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Caveolin-1 (cav-1) has been reported to regulate apoptosis, lipid metabolism and 
endocytosis. In the present study, we demonstrate that cav-1 can act as a potent 
immunomodulatory molecule in murine macrophages and play an important role in the 
development of fibrosis.  
In murine alveolar and peritoneal macrophages, loss of function experiments using 
siRNA showed that down-regulating cav-1 expression increased lipopolysaccharide (LPS)-
induced proinflammatory cytokine tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) 
production but decreased anti-inflammatory cytokine interleukin-10 (IL-10) production.  Gain of 
function experiments demonstrated that overexpression of cav-1 in RAW264.7 decreased LPS-
induced TNF-α and IL-6 production and augmented IL-10 production. Cav-1 interacted with 
TLR4 as revealed by co-immunoprecipitation in peritoneal macrophages. Overexpressing cav-1 
in RAW264.7 disrupted Toll like receptor 4 (TLR4) MyD88 and TRIF complex formation; 
regulated mitogen-activated protein kinase (MAPK) phosphorylation; and inhibited NF-κB 
activation. Furthermore, the anti-inflammatory modulation by cav-1 involved p38, since the 
administration of SB203580 significantly abrogated the effects of cav-1, and peritoneal 
macrophages isolated from MKK3 null mice did not demonstrate any modulation of cav-1. 
Interestingly, HO-1 translocated into caveolae after LPS stimulation. Carbon monoxide (CO), the 
gaseous byproduct of HO activity responsible for the anti-inflammatory effects of HO-1, did not 
regulate cytokines production in cav-1 null macrophages.  
We observed marked reduction of cav-1 expression in lung tissues and in primary 
pulmonary fibroblasts from IPF patients, compared to controls. Transforming growth factor-β1 
(TGF-β1), the well-known pro-fibrotic cytokine, decreased cav-1 expression in human pulmonary 
fibroblasts. Cav-1 was able to suppress TGF-β1-induced extracellular matrix (ECM) production 
in cultured fibroblasts through the regulation of the c-Jun N-terminal kinase (JNK) pathway. 
Interestingly, highly activated JNK was detected in IPF and bleomycin (BLM)-instilled lung 
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tissue samples, which was dramatically suppressed by adenovirus cav-1 infection. Moreover, 
JNK1 null fibroblasts showed reduced Smads cascades signaling, mimicking the effects of cav-1. 
We also demonstrated that cav-1 markedly ameliorated BLM-induced pulmonary fibrosis as 
evidenced by histological analysis, hydroxyproline content and immunoblot analysis.  
In summary, our data suggest that cav-1 acts as a potent immunomodulatory and anti-
fibrotic effector molecule. Cav-1 may mediate the anti-inflammatory effects of HO-1/CO in 
immune cells involving the MKK3/p38 MAPK pathway. Cav-1 also plays a pivotal role in ECM 
regulation and the development of fibrosis, possibly through the MAPK and Smads pathway. 
This study suggests cav-1 as a novel therapeutic target for patients with fibrosis and 
inflammation. 
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1.0  INTRODUCTION 
1.1 CAVEOLAE &CAVEOLIN-1 
1.1.1 Caveolae & Caveolin-1 (Cav-1) 
First described in the 1950s, caveolae are nonclathrin-coated plasma membrane 
microdomains rich in glycosphigolipids, sphingomyelin, and cholesterol (1-4). They are 
membrane vesicles with a diameter of 50 to 100 nm (5), which exist in single or cluster forms, 
with an appearance of flask-shaped membrane invaginations or flat pits, depending on the 
different stages of the invagination (6, 7). The actin cytoskeleton anchors caveolae (8-10). 
Caveolae are found in terminally differentiated cells, including endothelial cells, pneumocytes, 
fibroblasts, adipocytes and muscle cells (11).  
Originally, caveolae described vesicles performing clathrin-independent endocytosis (12, 
13). Many other functions are proposed for caveolae, including vesicular transportation 
(transcytosis of molecules across the cells, potocytosis and polonized protein trafficking, 
cholesterol transportation, calcium metabolism) (14-16), and most strikingly, the regulation of 
signal transduction (17-19). Caveolae are regarded as signalosome (11). Various receptors, 
intracellular signaling molecules, and proteins were reported to localize in caveolae (Figure 1) 
(20-22). Depending on different cell types and physiological status, caveolae exhibits  
multifunctional biological roles (15, 17, 23, 24). 
Caveolins are the major components of caveolae (11). Three caveolins have been 
identified to date in mammalian cells: cav-1, -2 and -3 (11). The human cav-1 and cav-2 genes 
are localized in the 7q31.1 region (25). The cav-1 gene contains three exons while the cav-2 gene 
contains two exons (26). Cav-1 and cav-2 are independent transcriptional units with an 
analogous last exon (27).  Human cav-3 gene is on chromosome 3p25 with two exons (28, 29). 
Cav-1 is the structural component and marker of caveolar microdomains (5). It has two isoforms 
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cav-1α (178 residues; 24 kDa) and β (147 residues; 21 kDa) (30−32). Whether the two isoforms 
arise from the same mRNA with different initiation or different mRNAs is still unclear (30, 33). 
Caveolae formed by different cav-1 isoforms have different molecular composition (30).  
 
 
 
 
Figure 1 Diagram of the composition of caveolae. Orange: Glycosphingolipids; Yellow: normal 
lipids; Blue: Caveolin; Red: GPI linked enzymes and receptors; Green: palmitolated, Src-like 
kinases trans-membrane receptors; grey and orange: caveolae associated signaling receptors. 
[Cell. 1992, 68:673-682, reference (34) ]  
 
Cav-1 has three distinct domains: the hydrophilic cytosolic N-terminal (1-101 residues), 
C-terminal (135-178 residues) and the hydrophobic central stretch (102-134 residues) (11). 
These characteristics make cav-1 form a hairpin-like structure with N and C termini orienting 
towards the cytoplasm (11). The cav scaffolding domain (82-101 residues) is essential for the 
formation of cav oligomers and interaction with other proteins (35, 36). The N-terminal 
membrane attachment domain (82-101 residues) and C-terminal membrane attachment domain 
(135-150 residues) are required for cav membrane attachment (37, 38). The C-terminal domain is 
also involved in protein-protein interactions (39). Cav-1 exists as an oligomeric complex of 14 to 
16 monomers (with a high molecular mass of 350-450 kDa.) through oligomerization domain 
(61-101 residues) (36). Cav-1 and cav-2 often co-express and associate (with a molecular weight 
of about 200-600 kDa) in endothelial cells, pneumocytes, fibroblasts and adipocytes (40). Cav-3 
expression is limited to muscle cells (28). Cav-1 is critical for the formation of caveolae. 
Transfection of cav-1 into cells lacking caveolae (lymphocytes, Caco-2 cells) induced caveolae 
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formation (41). Cav-2 null mice show no defects in caveolae formation (42). There are two kinds 
of post-translational modifications of cav-1: phosporylation of tyrosine 14 (43) and 
palmitoylation of cysteine 133, 143 and 156 (44). Phosporylation modifications are related to 
protein-protein interaction (45). Palmitoylation modifications are involved in cholesterol binding 
(38, 46). Conserved sequences of aromatic residues (ΦXΦXXXXΦ and ΦXXXXΦXXΦ, with Φ 
being Trp, Phe or Tyr) can be recognized by cav, and are called cav binding motifs (11, 47). 
Caveolae perform their signal transduction functions through compartmentalization of 
many signaling molecules and interaction with cav-1 (11). A wide variety of signaling proteins 
are reported to localize in caveolae and interact with cav-1 including: receptor tyrosine kinases 
and their downstream targets (EGFR, PDGFR, H-Ras, Raf-1, ERK, PI3K) (48-54); non-receptor 
tyrosine kinases (Src family, Fak) (53, 55); receptor serine/threonine kinases (TGFβ receptor 
type I) (56, 57); G-protein coupled receptors and the downstream molecules (G-protein alpha 
subunits, adenylyl cyclase, PKA, PKC isoforms) (47, 58-62); steroid hormone receptors (AR and 
ER) (63-65); eNOS etc. (66-68). Generally, the binding of the signaling molecules to cav-1 
results in their inactivation. For example, cav-1 is regarded as a tumor suppressor gene, since 
cav-1 interacts with growth factor receptors. Cav-1 binds EGFR via the cav binding motif within 
the kinase domain (DVWSYGUTUWEL), which inhibits autophosphorylation and activation of 
the receptor (48). Cav-1 binds to and inhibits MEK or ERK activation in a PDGF stimulation 
model (52).  
 
1.1.2 Cav-1 and inflammation 
The expression of cav-1 in immune cells was debated for a long time. Initially, caveolins 
were reported to be absent in macrophages (69). However, recently, with more specific elaborate 
detection methods, it is more convincing that caveolae and cav-1 exist in immune cells including 
mouse macrophages (5, 44, 50, 70, 71), human and bovine dendritic cells (72), human mast cells, 
and human lymphocytes etc. (42, 73). For mouse peritoneal macrophages (PM), evidences from 
immunoblot, RT-PCR, electron microscopy and immunofluorescence supported the existence of 
caveolae and cav-1 in the plasma membrane (69, 74, 75). Cav-1 expression is primarily on the 
plasma membrane, while cav-2 is located in the Golgi apparatus (74). Overexpression of cav-1 in 
non cav-1 expressing cells J774 led to the translocation of cav-2 to the plasma membrane (74). 
By immunoflurescence microscopy, cav-1 was detected in mouse bone marrow macrophages 
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(76). Rat resident peritoneal macrophages were also found to express cav-1 (77). The 
identification of cav-1 expression in macrophage like cell lines was controversial. By 
immunoblot and RT-PCR, THP-1 cells expressed cav-1 (78). Cav-1 mRNA was detected by RT-
PCR in RAW264.7 cells and J774 cells (74, 75). However they failed to detect cav-1 protein 
expression by immunoblot and immunoflurescence microscopy, though one previous reported 
described cav-1 expression in RAW264.7 cells (74, 75). Usually activation of macrophages led 
to increased cav-1 expression (74). For example, lipopolysaccharide increased cav-1 levels in 
peritoneal macrophages of C3HeB/FeJ mice (75). Upon elicitation by Freund’s adjuvant, the 
expression of cav-1 was increased in rat peritoneal macrophages and associated with an 
increased number of morphologically distinguishable caveolar invaginations as shown by 
electron microscopy (77). In THP-1 cells the expression level of cav-1 increased 50 fold upon 
differentiation into macrophages (78). However, one exception was that mouse resident and 
thioglycollate elicited peritoneal macrophages expressed cav-1 quantitatively similar to the level 
of 45% and 15% of that in NIH3T3 fibroblasts (74). The protein levels corresponded well with 
the mRNA levels as determined by ribonuclease protection assays (74).  
Macrophages exist in different functional subtypes according to environmental conditions 
(79). Alveolar macrophages (AM) are bone marrow-derived resident macrophages and play 
pivotal roles in pulmonary phagocytosis and inflammation (80, 81). Although Kasper et al. found 
cav-1 staining in rat alveolar macrophages by immunohistochemistry, they hypothesized that this 
was the result of phagocytosis of other cell type debris (82). Thus, studies of cav-1 in alveolar 
macrophages are absent and little is known about the expression and function of cav-1 in this cell 
type. In this study, we used two independent methods to detect cav-1 expression in mouse 
alveolar macrophages. 
The biological significance of cav-1 in macrophages is not clear. Cav-1 has been shown 
to play a role in apoptosis in macrophages (83, 84). When treated with various unrelated 
apoptotic agents, including simvastatin, camptothecin and glucose deprivation, in glycolate-
elicited mouse peritoneal macrophages, cav-1 expression was specifically and markedly 
increased, while cav-2 levels remained unaffected (83, 84). Cav-1 was shown to play a pivotal 
role in endocytosis and lipid metabolism in macrophages and play an active role in the 
pathophysiology of atherosclerosis (76, 85). Cav-1 can directly bind to cholesterol and lipid 
acids (76, 85, 86). CD36 and SR-BI, class B scavenger receptors, which bind HDL and 
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selectively transfer core cholesteryl-ester to the cells, localized in caveolae (70, 87). Transfection 
of cav-1 into J774 and RAW264.7 cells inhibited HDL-mediated cholesteryl-ester uptake (87). 
Increased cav-1 expression in THP-1 cells was associated with increased HDL cholesteryl-ester 
uptake and increased cholesterol efflux (88). Cav-1 was also found to be secreted, which might 
play a role in lipid removal and cholesterol retro-endocytosis (89).  
 The relationship between cav-1 and inflammation is mainly focused on uptake of antigen 
by antigen presenting cells (72), internalization of bacteria (90) and regulation of eNOS activity 
(91). Caveolae are known to be involved in non-clathrin coated endocytosis and may regulate the 
internalization of particles such as viruses and bacteria (90, 92-94). When treated with the 
caveolae inhibitor filipin, the speed of both fluid-phase and receptor-mediated endocytosis was 
decreased (95). In macrophages and mast cells, FimH mediated internalization of bacteria was 
dependent on caveolae-like vesicles (73, 90). The compounds that disrupt caveolae formation 
can effectively block bacterial uptake (73, 90). Stuart et al. reported that filipin and nystatin, 
drugs that specifically disrupt caveolae microdomains by cholesterol chelation, impaired the 
entry of C trachomatis serovar K. into J774A.1 cells (96). Cav-1 also suppresses inflammation 
via its interaction with and inhibition of eNOS activity (91, 97). Santizo et al. showed that 
downregulation of cav-1 combined with upregulation of eNOS decreased leukocyte adhesion in 
pial venules of ovariectomized female rats (97). Bucci et al. used the scaffolding domain of cav-
1 to inhibit edema formation and vascular leakage to the same extent as glucocorticoid in rats 
(91). In the present study, cav-1 was shown to have a direct effect on cytokine production in the 
LPS-induced inflammation model in mouse macrophages. 
 
1.1.3 Cav-1 and fibrosis 
Interstitial pulmonary fibrosis (IPF) is a progressive chronic interstitial lung disease with 
a high mortality (median survival of newly diagnosed patients is about 3 years) and a uniformly 
poor prognosis (98). The biochemical mechanism in the pathogenesis of IPF is still poorly 
understood (99). Current medical therapeutic drugs, such as corticosteroids, cytotoxic drugs and 
interferon-γ (IFN-γ) have been based on suppression of the inflammation and fibrosis process, 
but thus far have offered little benefit against the progression of the disease (100). Although 
there is no known etiologic stimulus that initiates IPF, many investigators believe that 
endogenous and exogenous stimuli injure the alveolar epithelium, followed by an abnormal 
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repair process (101). Among these processes, various cytokines and growth factors are critical 
(102). TGF-β1 has been implicated to be one of the important cytokines and chemokines in the 
initiation and progression of fibrosis (102). 
Recently, cav-1 has been reported to associate with TGF-β receptors by several 
investigators (56, 103). Schwartz et al. found that TGF-β receptor I (TGF-βRI) and TGF-βRII 
localize in cav-1 enriched fractions by density gradient fractionation in human endothelial cells 
(103). Furthermore, immunoprecipitation showed that cav-1 interacted with TGF-β receptors and 
regulated eNOS activation (103). Razani et al. reported that cav-1 interacted with TGF-βRI via 
the scaffolding domain of cav-1, inhibited the phosphorylation of Smad-2, disrupted its 
interaction with Smad-4 and prevented Smad-2 complex nuclear translocation in mouse 
fibroblasts (56). Moreover, many studies demonstrated that cav-1 expression is abnormal in 
experimental lung fibrosis (104-106). Tourkina et al. found that cav-1 expression is low in 
bleomycin-induced lung fibrosis tissue and scleroderma lung fibroblasts (104). Kasper et al. 
reported that cav-1 expression decreased with the treatment of CdCl2 and TGF-β1 in rat lung 
slices in vitro (106). They also reported loss of cav-1 expression in type I pneumocytes of rats 
and mini pigs in an irradiation-induced lung injury model, suggesting that low cav-1 expression 
might be an early indicator of subcellular alterations during lung fibrogenesis (105). Taken 
together with the studies of cav-1 knock out mice (107), which develop severe lung fibrosis, we 
hypothesize in the present studies that cav-1 might play a role in the pathogenesis of lung fibrosis 
by regulating ECM production. 
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1.2 HO-1& CO 
1.2.1 Heme oxygenase-1 (HO-1) 
HO, first identified in 1960s as a highly conserved enzyme, catabolizes the degradation 
of heme to generate biliverdin, iron and carbon monoxide (CO) (108, 109). Biliverdin is rapidly 
converted to bilirubin by biliverdin reductase (110). Iron binds to ferritin (110) (Figure 2). There 
are three isoforms of HO identified so far (111). HO-1 is highly inducible by a variety of stimuli, 
including hydrogen peroxide (H2O2), ultraviolet-A (320–380 nm) radiation, sodium m-arsenite 
(NaAsO2), heme, proinflammatory cytokines, bacterial endotoxins, growth factors, and tumor 
promoters (108). Furthermore, HO-1 responds to cellular stress related to oxygen tension such as 
hyperoxia and hypoxia (108). HO-2 and HO-3 are constitutively expressed (108). HO-1, also 
known as the stress protein HSP32, has a molecular weight of 30–33 kDa; HO-2 has a 
molecular weight of 36 kDa (108). Also, HO-1 and HO-2 differ in gene organization, structure 
and in chromosomal localization (108). HO-1 and HO-2, also known as Hmox1 and Hmox2, are 
the products of distinct genes (107). There are five exons and four introns in the human, mouse 
and rat HO-1 gene (107). According to fluorescence in situ hybridization, HO-1 and HO-2 genes 
localize to different chromatin regions. HO-1 lies in 22q12; while HO-2 lies in 16p13.3 (112). 
 
Figure 2 Diagram of heme metabolism. Heme oxygenase oxidizes heme to biliverdin-IX . The 
reaction requires 3 mol of molecular oxygen and NADPH:cytochrome P-450 reductase as a 
source of electrons. The cleavage of the heme ring releases the coordinated iron, as well as 
carbon monoxide (CO). The principal HO reaction product, biliverdin-IX , is further 
metabolized to bilirubin-IX  by biliverdin reductase. 
 7 
HO-1 is most abundant in tissues and cells involved in the uptake and degradation of 
plasma heme, including spleen, liver parenchyma, hematopoietic stem cells in bone marrow, 
kidney and macrophages (113). In other tissues or cells not directly involved in hemoglobin 
metabolism, the expression of HO-1 typically is low under basal conditions. However, HO-1 
levels increase dramatically in response to diverse cellular stress stimuli (113).  
Traditionally, HO-1 had been characterized as endoplasmic reticulum (ER) associated 
proteins, for two reasons: its activity was detected to be rich in microsomal (104,000g) fractions; 
the C-terminal hydrophobic domain of HO-1 indicates a typical membrane compartmentalization 
(114). This was confirmed by tranfection experiments. Shibahara et al. transfected rat HO-1 
cDNA into monkey kidney cells and found that HO-1 was highly expressed in the ER (115). 
Recently, HO-1 was found to localize in caveolae in pulmonary endothelial cells and in nucleus 
of primary astroglial cell (116, 117). 
HO-1 is highly inducible upon many stimuli, which cause oxidative stress (108).  And the 
regulation of HO-1 is primarily at the transcriptional level. Although there is report saying that in 
rat, message stability regulated by heat shock nuclear factor is one of the mechanisms in HO-1 
regulation (118). The mouse HO-1 gene contains one proximal and two distal enhancers (4kb 
and 10 kb upstream from the transcription initiation site) (118). LPS requires the distal enhancers 
to induce HO-1, while hypoxia does not (118). Promoter studies reveal the existence of the stress 
response element (StRE) in the enhancer regions of HO-1 gene (118). The mouse StRE contains 
AP-1 transcription factor bindig site. Mutation of the AP-1 binding site abolishes the HO-1 
upregulation by heavy metals, hydrogen peroxide, arsenate and LPS in vitro (119).  AP-1 
activation was also shown to mediate hyperoxia-induced HO-1 gene transcription in lung in 
accordance with STAT (120). AP-1 family includes Jun, Fos, NF-E2, Nrf1 and Nrf2. There are 
evidences that Nrf2 is of particular importance in regulation of HO-1 expression (108).    
It was also published that induction of HO-1 by hemorrhagic shock and resuscitation is 
primarily regulated by AP-1 ina ROS-dependent manner (121). Hypoxia-inducible factor-1 
(HIF-1) is also an important transcriptional activator, which binds to hypoxia response elements 
in mouse HO-1 gene. Mutation, which abolishes the HIF-1 binding site, also abolishes hypoxia-
induced HO-1 induction (122). IL-6 response element has been identified to involve in IL-1 
induction of HO-1 gene (123). 
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HO-1 serves as a protective gene by virtue of its anti-inflammatory, anti-apoptotic and 
anti-proliferative actions, manifested in a variety of cell types (116). In the present study, we will 
focus on the anti-inflammatory properties. All three byproducts of HO-1 were reported to 
mediate the protective function of HO-1 (116). CO has been shown to mimick the highly 
protective action of HO-1 in several rodent disease models (113). HO-1 expression or CO 
administration mediate the potent anti-inflammatory effects in monocytes and macrophages 
(124). Biliverdin and bilirubin are thought to contribute the protective effect largely because of 
their anti-oxidant properties (125, 126). Fe2+ induces ferritin expression, which is a multimeric 
iron-chelating protein, and it binds to free Fe2+ that would otherwise promote the generation of 
reactive oxygen species (ROS) and free radical (127).  
HO-1 demonstrated the anti-inflammatory properties in a lot of studies (116). HO-1 null 
mice had a chronic inflammation which progress with the age (128). And human reported to be 
deficient in HO-1 died from the inflammatory syndrome (129). The anti-inflammatory effects of 
HO-1 was also shown in many animal models including hypoxia (130), ischemic-reperfusion 
injury (131), endotoxin induced damage (132), atherosclerosis (52, 84), hypertension (133), 
allograft and xenograft transplantation (134) etc. Intratracheal adenoviral mediated HO-1 cDNA 
transfer into rat lung protected against the development of pulmonary damage during hyperoxia, 
as determined by pleural effusion volume and histological analysis. There were significant 
reductions of edema, hemorrhage, inflammation and apoptosis.  The survivability against 
hyperoxia also markedly increased in adenovirus HO-1 infected rats compared with the control-
infected rats (130). In an ischemic-reperfusion injury model in rat kidney, HO-1 induced by 
hemin reversed the impaired renal function after reperfusion, while SnPP, the chemical inhibitor 
of HO-1 activity, significantly inhibited the intercellular adhesion molecule ICAM-1 expression, 
activated caspase-3 expression and infiltration of macrophages (131), Another study in an acute 
lung injury model found that adenovirus HO-1 administration and hemin can both attenuate 
neutrophilic inflammation of the lung after aerosolized lipopolysaccharide (LPS) exposure. 
Interestingly, HO-1 gene was transferred to alveolar macrophages (AMs) besides the airway 
epithelium as revealed by immunohistochemical analysis. Moreover, overexpression of 
exogenous HO-1 in the macrophages had a high level of endogenous IL-10 production. 
Additionally, the increased production of IL-10 in the macrophages was critical for the resolution 
of neutrophilic migration in the lung after LPS exposure as evident from experiments using IL-
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10 knockout mice (132). In various other models, HO-1 significantly reduced edema, leukocyte 
adhesion and migration, inflammatory cytokines production, and death (135). Many reports 
indicate that CO can mediate the anti-inflammatory of HO-1 (136, 137). Many studies suggested 
that other by-products of HO activity also confer the cyto-protective effects.  
As mentioned before, biliverdin and bilirubin perform the cyto-protective effects 
probably through their anti-oxidant properties (125, 126, 138, 139). Bilirubin was shown to 
efficiently scavenge peroxyl radicals at micromolar concentrations in vitro. The anti-oxidant 
activity of bilirubin increased as the concentration of oxygen in the system is decreased from 20 
percent (normal air concentration) to 2% (physiological concentration). The anti-oxidant activity 
of bilirubin was even higher compared with that of alpha-tocopherol, which is thought to be the 
best suppressor of lipid peroxidation (138). In another model of heart ischemia-reperfusion 
injury model, exogenous bilirubin administration at the concentration of 100 namomolar 
efficiently restored myocardial function and suppressed infarct size and mitochondrial damage, 
mimicking the effects of overexpressing HO-1 by hemin. And HO-1 overexpressing was 
associated with increased bilirubin concentration in tissue and the perfusion buffer (139). 
HO-1 releases Fe2+ from the heme molecule. Free iron induces the expression of iron-
sequestering protein ferritin. It also activates the ATPase pump, which removes intracellular iron 
out of the cell. Extracellular iron chelator binds to iron, like desferoxamine mysylate (127).  
Ferritin appears to confer for HO-1 cyto-protective functions sometimes. In endothelial cells,  the 
expression of ferritin was the pathway by which HO-1 had oxidantive stress resistance (140). 
Heme administration markedly aggravated cytotoxicity with increased polymorphonuclear 
leukocyte oxidants and hydrogen peroxide. However, if the cells are briefly pulsed with heme 
and incubate for 16 hours, the cells become highly resistant to oxidant- mediated injury. An 
induction of both HO-1 and ferritin were observed. Apoferritin, when added to the cultures, was 
taken up in a dose-responsive manner. And it protected endothelial cells from the oxidant-
mediated injury. The mutant ferritin, which lacks the iron binding capacity and ferroxidase 
activity, has no cytoprotective effects (140).  In a hyperoxic lung injury model, ferritin was 
suggested to mediate the cyto-protective effects against hyperoxia instead of HO enzyme activity 
(127). However, in an endotoxin induced injury model, hemoglobin suppressed LPS-induced 
hepatic and renal functions, TNF alpha production, and neutrophil alveolitis. But pre-treatment 
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of iron binding protein desferoxamine and apoferritin failed to protect against the damage, 
suggesting that the cyto-protection provided by HO-1 is independent of ferritin (141). 
The present study will mainly focus on HO-1 / CO functions. 
1.2.2 Carbon monoxide (CO) 
Carbon monoxide was first discovered in the late 18th century and labeled as a toxic 
gaseous molecule. It is a colorless and odorless gase molecule, and one of the major pollutants 
from the incomplete combustion and oxidation of organic matter, like tobacco, wood and coal, 
etc. (113). Because of its higher affinity to hemoglobin (245 times that of oxygen), CO can 
displace oxygen from hemoglobin, shift the oxygen dissociation curve to the left, and lead to 
tissue hypoxia (113). Symptoms of CO toxicity include headache, dizziness and shortness of 
breath. And it happens when CO-Hb level reaches 20%. 50% - 80% CO-Hb will result in death. 
US environmental protection agency recommends the allowable exposure levels - 9ppm for 8 
hours or 35 ppm for 1 hour (142).  
In 1969, CO was discovered to be produced endogenous - generated form the heme 
degradation, which is thought to account for more than 75% CO production in the body (143). In 
healthy nonsmokers, basal levels of CO-Hb range from 1% to 3% and exhalation of CO ranges 
between 0 to 6 ppm. In smokers, CO-Hb range from 10% to 15%, and exhalation reaches 7 to 70 
ppm (144). Although it seems that increased CO content would be deleterious at first, recently, 
with more studies carried on, CO has been proposed to act as a signaling molecule rather than 
just a simply waste product (145). There are good evidences suggest that CO involves in the 
membrane potential gradients along and across the GI muscle layers. Along with the facts that 
CO is water soluable, it is not stored, and it diffuses quickly, CO seems to be a great cadidate for 
neurotransmitter. This hypothesis was confirmed by the report that genetic deficient of HO-2 
results in reduced size of inhibitory junctions, which can be restored by exogenous CO treatment 
(146). CO serves as a protective gaseous molecule by virtue of its anti-apoptotic effects. 
Exposure to exogenous CO suppressed TNF-α-induced apoptosis in mouse fibroblasts (124) and 
endothelial cells (147), similar to HO-1 over expression (124). In endothelial cells, p38 MAPK 
was demonstrated to be critical, as administration of SB203580, the selective chemical inhibitor 
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of p38, abolished the anti-apoptotic effects of CO (147). Furthermore, HO-1 or CO requires the 
activation of NF- B pathway to protect against TNF- -mediated endothelial cell apoptosis (148).  
CO exerts an anti-proliferative effect in a variety of cell types, including cancer cells, T cells, 
and smooth muscle cells (148, 149). In VSMC, exogenous CO application lead to G0 / G1 arrest, 
which involving the sGC pathway, p21 and p38 pathways (148, 149). In contrast, CO induced 
proliferation in endothelial cells (150).    
In many cellular and animal models, exogenously administrated of CO at low 
concentration (250 ppm) can modulate inflammatory responses (130, 136, 151, 152). As the 
severity of the inflammation increased (for example bacterial infection, asthma and diabetes), 
CO levels increased as evidenced by the increased CO exhalation in patients, as well as HO 
activity up-regulation (145, 153-155).  CO inhibited LPS induced tumor necrosis factor-α (TNF-
α) production and increased interleukin-10 (IL-10) production in RAW264.7 cells and mice 
(124).  Unlike NO, the effects are guanylate cyclase /cyclic GMP independent and involve the 
MAP kinase pathway, particularly MKK3/p38 MAP kinase pathway (124). CO was reported to 
be anti-inflammatory in the xenograft in the model of heart and lung. CO can inhibit platelet 
function and monocyte activation, which is thought to contribute to the suppression of the graft 
rejection (134, 156, 157). Also, CO was found to block eosinophil influx and inhibit interleukin-
5 (IL-5) production in allergen-challenged mice, suggesting that CO has anti-inflammatory 
effects in allergen-induced inflammation (134).   
The mechanisms underlying the effects of CO are far from completely understood. 
Soluble guanylyl cyclase (sGC) is one of the pathways. CO binds to the heme moiety of sGC, 
which activates cGMP. However, the capacity of NO-induced cGMP activation is 30-100 times 
higher compared with that of CO, despite the fact that the affinity of CO to sGC is equivalent to 
NO. Evidence suggests that NO is able to induce HO-1 and increae generation of CO, which in 
return inhibiting NOS activity, indicating HO-1 / CO as the feedback regulator of NO functions. 
NO is a vasorelaxant and also a potential free radical. HO might function to suppress NO free 
radical production while maintaining the vasodilatory properties by means of CO-induced cGMP 
production (142). In the last twenty years, CO is the second gas discovered to originate inside the 
body and have salutary effects besides NO. Certain findings indicate that HO-1 / CO and NOS / 
NO are functionally interrelated in mediating their protective effects (158, 159). CO induces the 
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expression of NOS in certain situations, while in others, inhibits expression of NOS / NO (160). 
In a TNF-α and -galactosamine-induced hepatitis mouse model, the protective action of CO 
was dependent on the activation of NF-κB, which triggers transcription of NOS with production 
of NO, and subsequently on the upregulation of HO-1 (161). It is well known that eNOS 
localizes in caveolae and that cav-1 regulates eNOS activity (86, 162). Here we are interested in 
the localization of HO-1 and its relationship to cav-1.  
MAPK signaling pathways have also been described as one of the mechamisms of CO-
mediated cyto-protection (142). Three MAPK pathways have been discovered – ERK, JNK and 
p38. All of them are reported to involve in CO-mediated effects depending on different 
experimental conditions and cell types. For example, CO inhibits T cell proliferation and IL-2 
production via ERK pathway (142).  CO inhibits TNF-alpha, IL-1 beta and macrophage 
inflammatory protein-1 production via p38 pathway (142).  CO decreases portal venous 
resistance and preserve hepatic function in an ischemia-reperfusion rat model via p38 pathway. 
Additionally, CO decreased IL-6 production through JNK pathway in response to LPS (142).  
CO has been decribed to activate K+ channels in a variety of tissues (142). Endogenously 
produced CO, by HO-2 in the arteries, inhibited vascular sensitivity to phenylephrine via the 
tetraethylammonium sensitive K+ channel (142). In human intestinal smooth muscle cells, CO 
activated a delayed K+ current resulting in membrane hyperpolarization. The current was blocked 
by quinidine. Ecogenous cGMP was able to restore the function. In rabbit corneal epithelial cells, 
exogenous CO activated a non-Ca2+-activated large conductance K+ channel with increased 
intracellular cGMP levels. CO also direct activated large conductance Ca2+-activated K+ channels 
through an interaction with histidine residues on the subunit, which was different from the 
mechanism of NO (through the ß subunit) (142). 
Other mechamisms might involves the binding of CO to ferrous heme containing 
proteins, including cytochrome c oxidase, cytochrome p450, NOS and some heme containing 
transcription factors (142). Some of these proteins seem to mediate the functions of CO. For 
example, CO binds to heme containing transcription factor NPAS2 and regulates circadian gene 
expression (163). CO binds to cytochrome p450 and inhibits its activity (164).  
 13 
2.0  THE ANTI-INFLAMMATORY EFFECTS OF CAV-1 
In the present study, we directly detect the expression of cav-1 in mouse alveolar 
macrophages and demonstrate its regulation of LPS-induced cytokine production in a variety of 
mouse macrophages. 
2.1 CAV-1 EXPRESSION IN ALVEOLAR MACROPHAGES 
We first examined cav-1 expression in mouse alveolar macrophages by immunoblot 
analysis. As shown in Figure 3A, the levels of cav-1 expressed in alveolar macrophages and 
peritoneal macrophages are similar, with increased levels observed in NIH3T3 mouse 
fibroblasts. To better characterize the expression of cav-1 in murine alveolar macrophages, we 
performed co-localization studies using antibodies specific for the mouse macrophage-specific 
marker Mac-3 (165) and cav-1.  Mac-3 immunostaining established that approximately 94% of 
cells derived from bronchoalveolar lavage (BAL) cells were macrophages. As shown in Figure 
3B, double immunofluorescence staining of BAL macrophages with Mac-3 and cav-1 
demonstrated cav-1 expression in alveolar macrophages. Cav-1 staining is mainly present on the 
surface and perinuclear compartments (Figure 3B) and extensively co-localizes with the Mac-3 
antigen (Figure 3B), a known macrophage plasma membrane marker. 
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Figure 3 Cav-1 expression in mouse alveolar macrophages. Mouse alveolar macrophages were 
isolated and cultured. (A) Cav-1 and β-actin expressions were determined by Western blot 
analysis in murine peritoneal macrophages and NIH3T3 fibroblasts. (B) Immunofluorescence 
staining of cav-1 and Mac-3 were performed in murine alveolar macrophages. To investigate the 
quality of the alveolar macrophages, we stained them with the murine macrophage specific 
marker Mac-3. Isolated cells were subjected to immunofluorescence microscopy. 5×100 cells 
were counted and the green staining cells were regarded as macrophages. The percentage of 
positive staining cell was 94±2%. Scale bar: 7 µm.
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2.2 THE ANTI-INFLAMMATORY EFFECTS OF CAV-1 
A 
2.2.1 Cav-1 regulates LPS-induced cytokines production 
To assess the function of cav-1 in macrophages, we isolated murine alveolar macrophages 
and investigated the modulation of cytokines production in response to LPS. We transfected 
siRNA targeting specific cav-1 mRNA sequences into these macrophages. At 24 hours post-
transfection, cav-1 protein levels were significantly decreased compared with that of the control, 
as evaluated by Western blot analysis (Figure 4A). Alveolar macrophages subjected to cav-1 
knockdown exhibited significant and selective augmentation of proinflammatory cytokines TNF-
α and IL-6 production and significant suppression of the anti-inflammatory cytokine IL-10 
production after LPS stimulation (Figure 4B-D).  
To further confirm whether cav-1 can modulate LPS-induced cytokine production, we 
used a cav-1 overexpressing RAW264.7 macrophage cell line. Overexpression of cav-1 caused 
marked attenuation of LPS-induced proinflammatory cytokines TNF-α and IL-6 and 
augmentation of anti-inflammatory cytokine Il-10 (Figure 5). 
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Figure 4 Modulation of LPS-induced cytokine production by down-regulating cav-1 expression 
in murine alveolar macrophages. Mouse alveolar macrophages were isolated and cultured. (A) 
The cells were transfected with siRNA of cav-1 and control siRNA for 24 hours. Cav-1 and β-
actin expressions were determined by Western blot analysis. After 24 hours post-transfection, the 
culture medium of transfected peritoneal macrophages was harvested with or without LPS 
treatment for 4 hours. TNF-α (B), IL-6 (C) and IL-10 (D) cytokine production was determined 
by ELISA. Values were mean ± S.E., n = 3.  
 
2.2.2 Cav-1 interacts with TLR4 and regulates TLR4 signaling 
We next attempted to delineate the possible downstream mechanism by which cav-1 exerts 
its anti-inflammatory effects. It has been previously demonstrated that the effects of LPS on 
macrophages require recruitment of an LPS receptor complex (TLR4 and MD-2) to lipid rafts 
containing CD14 (166). Walton et al. reported that LPS induced membrane translocation of 
TLR4 and MD-2 to caveolar fractions of human aortic endothelial cells, by cell fractionation and 
immunofluorescence analyses (89, 167). Cav-1 has been reported to regulate membrane receptor 
signaling either by direct binding or through interaction with the downstream signaling 
molecules (22).  
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Figure 5 Over-expressing cav-1 in RAW264.7 modulates LPS-induced cytokines production. 
RAW264.7 cells stably transfected with cav-1, were serum starved for 24 hours and 
administrated LPS for 2 and 4 hours. The culture medium was harvested. (A) TNF-α (B) IL-6 
and (C) IL-10 were determined by ELISA. Values were mean ± S.E., n = 3.  
 
 
Interestingly, TLR4 contains a putative cav-1 binding motif (739FIQSRWCIF747) (11). It is 
possible that cav-1 may interact with the TLR4 complex and regulate its downstream effector 
functions. 
We tested our hypothesis by co-immunoprecipitation. As demonstrated in Figure 6A and 
B, the antibody against TLR4 can pull down cav-1 protein and the antibody against cav-1 can 
pull down TLR4 protein. These data supported the interaction of cav-1 and TLR4 in the caveolar 
fraction of peritoneal macrophages. 
Next, we determined the effects of cav-1 on TLR4 signaling. We tested whether cav-1 can 
affect TLR4 complex formation with MyD88 and TRIF. With cav-1 overexpression, MyD88 and 
TRIF association with TLR4 was markedly decreased (Figure 6C). 
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We next tested the hypothesis that cav-1 binds to TLR4 through the putative cav-1 
binding motif. We performed PCR-based site-directed mutagenesis to mutate the two aromatic 
amino acid residues into Ala (Figure 7A) and inserted the construct into a Flag tagged expressing 
plasmid. We transfected the constructs into RAW264.7 (Figure 7B) and subjected them to co-
immunoprecipitation. As shown in Figure 7C, the mutant transfectants did not interacted with 
TLR4 compared to the wild type, suggesting that cav-1 interacts with TLR4 through the cav-1 
binding motif. 
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Figure 6 Cav-1 affects TLR4 signaling. (A, B) TLR4 interacts with cav-1.  Peritoneal 
macrophages were isolated. The cells were serum starved for 12 hours. The caveolar fraction was 
isolated and subjected to immunoprecipitation and Western blot analysis. (C) Cav-1 decreased 
TLR4 complex formation after LPS stimulation. Cav-1 overexpressing and vector control cells 
were serum starved for 24 hours and treated with LPS for different time points. The cells were 
harvested and subjected to immunoprecipitation and Western blot analysis. 
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Figure 7 Cav-1 interacts with TLR4 through the cav-1 binding motif. (A) The designed mutation 
site and sequences of TLR4. (B) The WT and MT constructs were transfected into RAW264.7 
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cells. The cells were subjected to Western blot analysis. (C) After transfection, the cells were 
serum starved and subjected to co-immunoprecipitation as indicated. WT: wild type; MT: 
mutant. 
 
2.2.3 Cav-1 modulates NF-κB signaling  
NK-κB is well-known transcription factor that regulate LPS-induced cytokine production 
(168). We next investigated if cav-1 modulates the transcription factor NF-κB pathway. Cav-1 
stably transfected RAW264.7 cells and vector control cells were treated with LPS. Cytosolic 
protein and nuclear extracts were obtained at different time points. We detected IκBα 
phosphorylation to indicate IKK activity and NF-κB p65 phosphorylation in the cytosolic 
fraction by immunoblot analysis. As shown in Figure 7A and B, LPS-induced IκBα and p65 
phosphorylation in the cytosol was markedly inhibited in the cav-1 overexpressing cells 
compared to that of the control cells. Nuclear translocation of NF-κB p65 was significantly 
reduced as revealed by immunoblot analysis (Figure 8B). By immunofluorescence staining, we 
observed that p65 nuclear translocation occurred as early as 5 mins, while in control cells the 
translocation was rare at 5 min (Figure 8C). After 15 min, we observed significant p65 nuclear 
translocation in cav-1 overexpressing cells (data not shown). We also tested NF-κB activity by 
electrophoretic mobility shift assay (EMSA). Control cells treated with LPS showed a predicted 
increase in NF-κB binding activity; whereas cav-1 overexpressing cells treated with LPS showed 
a marked reduction in NF-κB binding activity (Figure 8D). 
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Figure 8 Cav-1 modulates NF-κB signaling. Cav-1 stably transfected RAW264.7 cells and 
control cells were treated with LPS. (A, B) Cytosolic protein and nuclear extracts were obtained 
at different time points and subjected to Western blot analysis for phospho-IκBα, IκBα, NF-κB 
phospho-p65, NF-κB p65. (C) Immunofluorescence staining for NF-κB p65 after 5 min LPS 
induction in RAW264.7 cells stably transfected with cav-1 and vector. (D) EMSA for NF-κB 
binding activity at different times of LPS induction.  
 
2.2.4 Cav-1 modulates the MAPK pathway 
Given that MAPK (ERK1/2) and PI3K mediate cytokine production and are regulated by 
cav-1 in fibroblasts and endothelial cells (169, 170), we examined whether MAPK and PI3K are 
modulated in cav-1 overexpressing RAW264.7 cells. LPS-induced activation of ERK1/2 MAPK, 
JNK MAPK and PI3K was significantly decreased while p38 MAPK activation was significantly 
increased in cav-1 overexpressing cells (Figure 9). 
Because PI3K and all three MAPK pathways were regulated by cav-1, we tested which 
pathway attenuation would lead to a loss of cytokine modulation by cav-1. UO126 (the inhibitor 
of MEK1/2, upstream kinase of ERK) decreased TNF-α and IL-10 production compared with 
DMSO/LPS treatment (Figure 10). Wortmannin (the inhibitor of PI3K) decreased IL-10 
production compared with DMSO/LPS treatment. SB203580 (the inhibitor of p38 MAPK) and 
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SP600125 (JNK inhibitor) decreased TNF- α, IL-6, and IL-10 cytokine production. We observed 
significant differences in cytokine production (TNF-α, IL-6, and IL-10) between cav-1 
overexpressing and control vector RAW264.7 cells in DMSO/LPS, UO126/LPS, and 
wortmannin/LPS treatments. These findings suggest that ERK1/2 and PI3K pathways are not 
involved in the regulation of cytokine production by cav-1. However, SB203580, the inhibitor of 
p38 MAPK, eliminated the differences of TNF-α, IL-6, and IL-10 production between cav-1 
overexpressing RAW264.7 and vector control cells. Administration of JNK inhibitor SP600125 
had no effect on the modulation of the cytokine TNF-α and IL-10 production by cav-1, whereas 
reversed the modulation of cav-1 on IL-6 production. We observed that cav-1 increased p38 
phosphorylation (Figure 9) while decreasing other MAPKs and PI3K activation. Chemincal 
inhibition of p38 activation eliminated the modulation of LPS-induced TNF-α, IL-6, and IL-10 
production by cav-1. To explore further the role of p38 MAPK, we isolated mouse PMs from 
MKK3 (a major upstream kinase of p38) null mice and wild-type littermates and transfected with 
siRNA of cav-1. Decreasing cav-1 in MKK3 (-/-) macrophages had no effect on LPS-induced 
TNF- α, IL-6, and IL-10 production compared with the control siRNA transfectants (Figure 11). 
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Figure 9 Modulation of MAPK and PI3K pathway by cav-1. After serum starvation for 24 h, 
RAW264.7 cells stably transfected with cav-1 gene and with control vector were treated with or 
without LPS for 10 min, 20 min, and 60 min. The cells were harvested and subjected to Western 
blot analysis for phosphorylated ERK1/2, JNK, p38, and Akt. The same blots were washed and 
blotted for total ERK1/2, JNK, p38, and Akt as the loading control.  
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Figure 10 The p38 and JNK pathway are involved in the regulation of cav-1 on cytokines 
production. RAW264.7 cells stably transfected with cav-1 gene (filled bars) and with control 
vector (open bars) were serum starved for 24 h. The cells were pretreated for 2 h with DMSO 
with or without chemicals, including UO126, Wortmannin, SB203580, and SP600125. The 
treated cells were then administrated LPS for 4 h. The culture media were harvested. Cytokines 
levels in culture medium (A) TNF-α, (B) IL-6, and (C) IL-10 were determined by ELISA. 
Values were mean ± S.E., n = 3. 
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Figure 11 MKK3/p38 mediates the modulation of LPS-induced cytokine production by cav-1. 
PMs were isolated and cultured from MKK3 (+/+) and MKK3 (-/-) mice. (A) To investigate the 
quality of the macrophages, we performed murine macrophage–specific marker Mac-3 staining. 
For PMs, the cells were subjected to flow cytometry. The percentage of positive staining cells 
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was 95%. The cells were transfected with siRNA for cav-1 and the control siRNA. At 24 h 
posttransfection, the cells were treated with or without LPS for 4 h. The effects of siRNA 
transfection were determined by Western blot analysis (B).The culture medium was harvested. 
Medium cytokine levels TNF-α (C), IL-6 (D), and IL-10 (E) were determined by ELISA. Values 
were mean ± S.E., n = 3. 
2.2.5 Cav-1 modulates AP-1 transcriptional activity 
AP-1 is also a well-known transcription factor that regulate LPS-induced cytokine 
production (168). We hypothesized that cav-1 might also attenuate LPS-induced AP-1 activation. 
Cells treated with LPS showed a predicted increase in AP-1 binding activities, whereas cav-1 
overexpressing cells treated with LPS showed a marked reduction in AP-1 binding activities 
(Figure 12A).  
We next examined whether p38 MAPK was involved in the suppression of transcription 
factor AP-1 and NF-κB activation by cav-1. SB203580, the inhibitor of p38, was administered to 
RAW264.7 cells stably transfected with cav-1 gene and vector. Cav-1 attenuated the LPS-
induced activation of NF-κB and AP-1. When SB203580 was added, the activation of NF-κB 
and AP-1 were similarly inhibited in vector-transfected cells as in cav-1 overexpressing cells 
(Figure 12B). SB203580 eliminated the attenuation of cav-1 on NF-κB and AP-1 activation, 
suggesting that p38 was involved in the suppression of cav-1 on LPS-induced inflammatory 
transcription factor activation 
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Figure 12 Effects of cav-1 on LPS induced AP-1 activation (A). RAW264.7 cells stably 
transfected with cav-1 gene and with control vector were serum starved for 24 h. After treatment 
with LPS for 0 min, 5 min, 15 min, 30 min, and 1 h, the cells were harvested. Nuclear proteins 
were extracted and subjected to EMSA for AP-1 activation. (B) Effects of SB203580 on LPS 
induced NF-κB and AP-1 activation. After serum starvation, RAW264.7 cells stably transfected 
with cav-1 gene or with control vector were pretreated with SB203580 or DMSO for 1 h. The 
nuclear proteins were extracted and subjected to EMSA for NF-κB and AP-1 activation. Cold 
oligonucleotides containing the transcription factor-binding site for NF-κB and AP-1 were added 
as a competition control, and cold oligonucleotides containing SP1 binding site were added as a 
negative competition control.  
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2.3 CAV-1 MEDIATES THE ANTI-INFLAMMTORY EFFECTS OF HO-1 & CO 
Cav-1 
1   2   3    4   5    6   7    8   9   10  11  12 
HO-1 
CTL
LPS
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CTL
2.3.1 HO-1 localizes in caveolae after LPS stimulation 
Given the fact that cav-1 has the similar effects as HO-1 in the regulation of LPS-induced 
cytokine production and p38 MAPK pathways, we are interested in finding the relationship 
between these two molecules. We first tested if these two molecules are co-localized in mouse 
peritoneal macrophages. We observed that in the resident state, cav-1 localized with HO-1 in the 
high density sucrose fraction, but not in the low density sucrose fraction which is the typical 
caveolar fraction. After LPS stimulation, a notable potion of HO-1 translocated into the caveolar 
fraction and co-localized with cav-1 (Figure 13A). Taking advantage of the fact that caveolae are 
rich in cholesterol and Triton-X 100 insoluble at 4 0C, we isolated caveolae using 
ultracentrifugation (171). Consistently, HO-1 was only found in detergent soluble fraction in the 
resident state, while HO-1 was observed in detergent insoluble fraction after LPS (Figure 13B) 
and hemin stimulation (data not shown). 
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Figure 13 HO-1 translocates into the caveolae after LPS stimulation. Peritoneal macrophages 
were isolated and subjected to LPS stimulation for 16 hours. (A) The cells were harvested. 
Sucrose density ultracentrifugation was performed. 12 fractions were subjected to Western blot 
analysis. (B) 1% Triton-X 100 MBS buffer was used to homogenize the cells prior to 
ultracentrifugation. The pellets were the detergent resistant fraction: DR. The supernatant was 
the detergent soluble fraction: DS. (C) Peritoneal macrophages were isolated and cultured. The 
cells were subjected to immunofluorescence staining for HO-1 and Cav-1. Confocal microscopy 
was used to identify the co-localization. Arrow indicates yellow color.  
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 Next, we were interested in the question of whether HO-1 translocated into caveolae is 
functionally active. So we isolated the caveolar fraction of peritoneal macrophages and used the 
other fractions as the non-caveolar fraction control. As shown in Figure 14, HO activity in 
caveolar faction is increased after LPS treatment as well as in non-caveolar fractions. The SnPP 
treated and the non-LPS stimulated samples had low bilirubin content, similar as boiled proteins, 
indicating that HO-1 activity in caveolae is inducible and specific. We noticed the relative small 
HO-1 protein content in caveolae. So although it looks that the total HO-1 activity is higher in 
cytosol on per mg protein basis, actually, HO activity was higher in caveolae than in non-
caveolar fraction if standardized with the same HO-1 protein.  
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Figure 14 HO activity in caveolae. Peritoneal macrophages were isolated and cultured. The cells 
were serum starved and stimulated with LPS. The proteins were subjected to caveolar 
fractionation as indicated in methods. HO activity was determined. * indicated p<0.05 as 
compared to non-LPS stimulation. # indicated p<0.05 as compared to LPS induced HO activity 
in caveolar fraction. 
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2.3.2 The mechanism of the translocation of HO-1  
We were interested in the mechanism of the translocation of HO-1. Previous publications 
indicate that PKCs were involved in membrane protein trafficking (172). Also, p38 was 
reported to be critical in the anti-inflammatory effects of HO-1 (145). We chose PKC and p38 
as our potential candidates here. We found that inhibition of PKC by GF 109203X did not 
affect LPS-induced HO-1 translocation. Interestingly, inhibition of p38 by SB203580 markedly 
suppressed HO-1 translocation (Figure 15A). To further investigate the involvement of p38, we 
isolated some peritoneal macrophages from MKK3 null mice. As shown in Figure 15B, HO-1 
translocated into the caveolar fraction after LPS stimulation in wild type macrophages. In 
MKK3 null cells, the existence of HO-1 in the caveolar fraction was significantly reduced after 
LPS compared with wild type cells. As a control, we found that hemin stimulation also induced 
the HO-1 membrane translocation, which was not affected by MKK3 knockout. These data 
supported that HO-1 translocation into caveolae is dependent on p38 in particular.  
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Figure 15 LPS-induced HO-1 translocation into caveolae dependent on MKK3 / p38 pathway. 
(A) Peritoneal macrophages were isolated from C57BL/6 mice. The cells were treated with GF 
109203X or  SB 203580 for 1 hour. Then LPS was administrated. The cells were harvested and 
caveolar fractions or whole cell lysates were isolated and subjected to Western blot analysis for 
HO-1, cav-1, or β-actin (B) Peritoneal macrophages were isolated from MKK3 null mice and 
wild type littermates. The cells were treated with hemin or LPS. The cells were then harvested 
and subjected to caveolar fraction isolation and Western blot analysis for HO-1 and cav-1. The 
whole cell lysates were also harvested and use as a control. 
 
2.3.3 Cav-1 mediates the anti-inflammatory effects of CO 
Cav-1 and HO-1 have similar anti-inflammatory effects in the regulation of LPS-induced 
cytokines production. TLR4 and HO-1 both localize in caveolae together with cav-1. We 
hypothesized that cav-1 may mediate the anti-inflammatory effects of HO-1 or that HO-1 
mediates the effects of cav-1. We used the peritoneal macrophages isolated from cav-1 null mice 
to investigate the hypothesis. As demonstrated in Figure 16, 250 ppm CO inhibited LPS-induced 
TNF-α and IL-6 production. The effects of CO were lost in cav-1 null mice. These data 
suggested that cav-1 mediates the anti-inflammatory effects of CO. 
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2.3.4 Cav-1 regulates LPS-induced cytokines production independent of HO-1 
We also tested the possibility that HO-1 mediates the anti-inflammatory effects of cav-1. 
e used SnPP to inhibit HO activity in RAW264.7 cells overexpressing cav-1 or vector control. 
s shown in Figure 17, overexpressing cav-1 still inhibited LPS-induced TNF-α and IL-6 
roduction after the administration of SnPP.  
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2.3.5 CO modulates cav-1 expression and interaction with TLR4 
Previously, we showed that cav-1 interacted with TLR4 (Figure 6A). The interaction 
disrupted TLR4 complex formation (Figure 6B). Together with the data that cav-1mediates CO 
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induction was increased after 24 hours CO treatment. Administration of hemin, the substrate of 
HO-1, which induced HO-1 activation, increased TLR4 interaction with cav-1 (Figure 18B). CO 
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2.3.6  Summary 
Cav-1 was demonstrated to have anti-inflammatory effects in macrophages in this chapter.  
First, cav-1 was shown to exist in mouse alveolar macrophages, mainly localized in plasma 
membrane and peri-nuclear areas. Down-regulating cav-1 by siRNA increased pro-inflammatory 
cytokines (IL-6 and TNF-α) production and decreased anti-inflammatory cytokine (IL-10) 
production in mouse peritoneal and alveolar macrophages. Up-regulation of cav-1 by stable 
transfection decreased pro-inflammatory (IL-6 and TNF-α) cytokines production and increased 
anti-inflammatory (IL-10) cytokine production in RAW264.7 macrophage cell line. A cav-1 
binding motif was identified within the c-terminal region of TLR4 protein. Co-
immunoprecipitation and site-directed mutagenesis further confirmed that cav-1 binds to TLR4 
via its binding motif. The association of cav-1 and TLR4 disrupted adaptor molecule MD-2 and 
TRIF recruitment. Overexpressing cav-1 in RAW264.7 cells marked inhibited NF-κB signaling. 
IKK activity was reduced. NF-κB p65 phosphorylation and nuclear translocation was inhibited. 
EMSA showed that cav-1 suppressed AP-1 and NF-kB transcriptional factor activity. MAPK 
pathway was also affected by cav-1 stable transfection. MKK3 / p38 pathway was shown to 
involve in the regulation of cytokines production by cav-1.  
HO-1, the cyto-protective gene, was shown to translocate into caveolae and co-localize 
with cav-1 after LPS stimulation. The trafficking of HO-1 was dependent on p38. The caveolar 
HO-1 had HO activity and CO was generated in sites of caveolae. Exogenous CO administration 
is able to increase the interaction between TLR4 and cav-1. This LPS-induced HO-1 trafficking 
loop is appeared to be an important negative regulation mechanism for dampening LPS signal 
and protection for the cell. 
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3.0  THE ANTI-FIBROTIC EFFECTS OF CAV-1 
In the present studies, we tested our hypothesis that cav-1 might be involved in the 
pathogenesis of lung fibrosis and regulate ECM production by several independent ways. We 
extensively investigated cav-1 expression in lung tissue and fibroblasts from IPF patients and 
control subjects. We report for the first time that cav-1 confers anti-fibrotic effects both in vitro 
and in vivo. Our data suggest that cav-1 is an important regulator in the pathogenesis of 
pulmonary fibrosis and indicate an exciting and promising potential role for cav-1 in the therapy 
for pulmonary fibrosis. 
3.1 ALTERED CAV-1 EXPRESSION IN IPF 
Cav-1 expression was reported to decrease in experimental animal models of pulmonary 
fibrosis (173-175). To determine whether expression of cav-1 was altered in patients with IPF, 
we looked for cav-1 gene expression in an IPF dataset previously described. We observed a 2 
fold reduction in cav-1 mRNA in IPF lung tissues (P = 0.000087, Figure 19A). We found a 
similar decrease in another dataset (20) that we recently published (data not shown). The 
reduction of cav-1 protein expression was confirmed by densitometric analysis of immunoblots 
(Figure 19B) and by immunohistochemistry staining (Figure 19C). Among the 14 lung tissue 
samples examined (7 IPF patient and 7 control subject), cav-1 protein expression was decreased 
by approximately 73% in IPF patients as measured by the ratio of band densitometric units of 
cav-1 to β-actin compared to the controls (P = 0.035, Figure 19B).   
Fibroblasts play an active role in ECM production, deposition and chemokine signaling 
during the process of pulmonary fibrosis (176). We next examined cav-1 expression in human 
pulmonary fibroblasts (4 IPF and 5 control). We observed marked reduction of cav-1 mRNA 
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expression in primary pulmonary fibroblasts derived from IPF patients compared to control 
subjects (P = 0.037, Figure 19D). Similarly, cav-1 protein expression was decreased in primary 
fibroblasts from IPF patients compared to control subjects (P = 0.014, Figure 19E).  
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Figure 19 Altered cav-1 expressions in IPF patients. (A) Microarray analysis of Cav-1 mRNA 
reveals a significant reduction (p = 0.000087, fold 0.5) in IPF patients (n=13) compared to 
controls (n=11). (B) Cav-1 protein expressions as detected by Western blot analysis in lung 
tissue samples from IPF patients (n = 7) and control subjects (n = 7). 3 representative samples of 
patient and control were shown. (C) Immunohistochemical analysis of cav-1 expression in lung 
tissue sections. Green indicates cav-1; blue indicates nucleus; orange indicates α-SMA. A 
representative example out of seven for patient sample or control subjects was shown. (Original 
magnification, x20.) (D) Cav-1 mRNA expressions were detected by Taqman PCR in pulmonary 
fibroblasts derived from IPF patients (n=4) and control subjects (n=5) (E) Cav-1 and β-actin 
protein expressions were determined by Western blot analysis in pulmonary fibroblasts derived 
from IPF patients (n=4) and control subjects (n=5). 3 representative samples of patient and 
control were shown. The differences in mRNA level of cav-1 expression were compared by 
Student’s t-test. The differences in protein level of cav-1 expression were compared by Wilcoxon 
two-sample test. The differences were considered significant at p<0.05. 
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3.2 TGF-β1 REGULATES CAV-1 EXPRESSION IN PULMONARY FIBROBLASTS 
 
TGF-β1 is one of the key cytokines involved in pulmonary fibrosis (102). Its level, contrary 
to cav-1 expression, increases significantly in active fibrotic areas (102), which leads to the 
hypothesis that TGF-β1 might be one of the negative regulators of cav-1 expression. To test this 
hypothesis, we administered TGF-β1 to primary human pulmonary fibroblasts and to the human 
pulmonary fibroblast cell line MRC-5. As detected by Taqman PCR, mRNA of cav-1 decreased 
in primary fibroblasts (P = 0.0024) and in MRC-5 (P = 0.0002; Figure 20A) after 1 day of 
treatment with TGF-β1. We also observed decreased cav-1 protein expression after TGF-
β1 treatment in a time and dose-dependent manner (Figure 20B,C). 
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Figure 20 TGF-β1 regulates cav-1 expression. (A) Human primary pulmonary fibroblasts and 
MRC-5 cells were treated with 4 ng/ml TGF-β1 for 24 hours. Cav-1 mRNA levels were 
determined by Taqman PCR. (B) The same cells were treated with different concentrations of 
TGF-β1 for 24 hours; (C) or treated with 4 ng/ml TGF-β1 for 1 day and 2 days. Cav-1 protein 
levels were determined by Western blot analysis.  
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3.3 CAV-1 SUPPRESSES TGF-β1 INDUCED ECM PRODUCTION IN PULMONARY 
FIBROBLASTS 
In view of our observations that the profibrotic TGF-β can reduce cav-1 expression, we 
examined the function of cav-1 in response to TGF-β.  We tested the hypothesis that cav-1 is 
capable of modifying ECM production. We used both gain of function and loss of function 
experiments to test our hypothesis.  We first performed gain of function experiments; we 
generated an adenovirus expressing cav-1 gene to upregulate cav-1 expression in MRC-5.  Cav-1 
expression markedly increased in a dose-dependent manner after Ad-cav-1 infection of MRC-5 
(Figure 21A), with optimal cav-1 expression at 2 days post-infection and maintained for 4 days 
(Figure 21B).  Using this adenovirus, we found that overexpressing cav-1 significantly 
suppressed ECM production including collagen type I and fibronectin, and α-smooth muscle 
actin (SMA), an indicator for fibroblast activation (Figure 21C). This observation was further 
confirmed by stable transfection experiments. Likewise, TGF-β1-stimulated ECM production 
including collagen type I and fibronectin and  α-SMA, were markedly reduced in cav-1 stably 
transfected MRC-5 compared with the vector transfected control cells (Figure 21D,E). We then 
performed loss of function experiments. Transfection of siRNA targeting human cav-1 
effectively reduced cav-1 expression in MRC-5 (Figure 21F).  Down regulation of cav-1 
markedly enhanced α-SMA, collagen type I, and fibronectin production (Figure 21G). Taken 
together, cav-1 appears to be a promising protective molecule in pulmonary fibrosis because of 
its powerful ability to suppress ECM production and fibroblasts transformation. 
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Figure 21 Cav-1 suppresses TGF-β1 induced ECM production. (A) Western blot analysis of cav-
1 expressions in MRC-5 cells infected with different dosage of ad-cav-1 or ad-lacZ virus for 48 
hours. (B) infected with 100 pfu/cell cav-1 adenovirus or lacZ virus or not for 1 to 4 days. (C) 
After adenovirus infection, 4 ng/ml TGF-β1 was added to MRC-5 for 2 days. ECM productions 
were determined by Western blot analysis. (D) Western blot analysis of cav-1 expressions in 
MRC-5 cells stably transfected with cav-1 and vector. (E) ECM productions in cav-1 stable 
transfected and control MRC-5 cells after 2 days TGF-β1 treatment of 4 ng/ml. (F) Western blot 
analysis of cav-1 expressions in MRC-5 cells transfected with siRNA targeting human cav-1 or 
control siRNA for 24 hours. (G) After siRNA transfection for 24 hours, the MRC-5 cells were 
serum starved overnight and treated with 4 ng/ml TGF-β1 for 2 days. ECM productions were 
determined by Western blot. 
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3.4 CAV-1 GENE TRANSFER VIA ADENOVIRUS SUPPRESSES BLM-INDUCED 
PULMONARY FIBROSIS 
Based on our in vitro observations that cav-1 can attenuate TGF-β1-induced ECM 
production, we further tested whether cav-1 can attenuate ECM production using the BLM 
induced pulmonary fibrosis model in vivo. We effectively transferred the cav-1 gene into mouse 
lung tissue by intratracheal instillation of Ad-cav-1 (Figure 22A,B). Lung histopathological 
changes were assessed after BLM in saline, Ad-lacZ or cav-1 treated animals (Figure 22C, D).  
For groups without BLM treatment, alveolar architecture was preserved (Figure 22C). No 
significant differences were observed among saline, ad-lacZ and ad-cav-1 groups (Mean fibrosis 
scores: 0.12 ± 0.12, 0.49 ± 0.43 and 0.56 ± 0.06, respectively, P = 0.162, Figure 22E).  Collagen 
accumulation, an index of lung fibrosis, as determined by the measurement of hydroxyproline 
content of the left lung, was low and similar (111.58 ±18.9 µg, 133.6 ± 24.2 µg and 144.2 ± 27.7 
µg, respectively, P = 0.1987, Figure 22F). Consistently, immunoblots of the homogenized protein 
of lung tissue demonstrated low ECM production and absence of Smad-2 activation (Figure 
22G). TGF-β1, one of the key cytokines involved in pulmonary fibrosis (177), was found to be 
low by ELISA (Figure 22H). 
In contrast, for groups with BLM treatment, lung tissue sections in either saline or ad-
lacZ instilled groups showed extensive patchy areas of regional interstitial fibrosis with marked 
disruption of the alveolar unit, increased thickening of the interstitium and inflammation.  
However, in the ad-cav-1 group, the structural integrity of the lung was less severely affected, 
with less evidence of fibrotic obliteration, destruction of alveolar units and inflammatory cells 
infiltration (Figure 22 C,D). Mean fibrosis scores were significantly reduced in ad-cav-1 group 
compared with the lacZ and saline groups (2.83 ± 0.85, 2.18 ± 0.70 and 0.52 ± 0.45 in saline, ad-
lacZ and ad-cav1 group respectively, over all P = 0.0056, lacZ and cav-1, P = 0.0009, Figure 
22E). The hydroxyproline content was increased after BLM treatment. While ad-cav-1 mice had 
a markedly reduced hydroxyproline levels compared with lacZ and saline mice (226.1 ± 29.7 µg, 
226.8 ± 8.2 µg and 178.4 ± 19.7 µg in saline, ad-lacZ and ad-cav1 group respectively, over all P 
= 0.0048, lacZ and cav-1, P = 0.001, Figure 22F). Consistently, immunoblot analysis revealed 
that ad-cav-1 treatment dramatically suppressed fibronectin and collagen deposition compared 
with the lacZ group (Figure 22G).  As we expected, TGF-β1 was increased along with the 
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fibrosis development after BLM administration. While it was significantly decreased in ad-cav-1 
infection group compared with lacZ group (Figure 22H). The Smad-2 phosphorylation was also 
markedly diminished by ad-cav-1 infection (Figure 22G).   
To further explore the therapeutic potentials of ad-cav-1, we also infected the mice with 
adenovirus carrying lacZ or cav-1 gene seven days post-BLM instillation. One week later, the 
whole lung was subjected to hydroxyproline content determination. Ad-cav-1 infection was still 
capable of suppressing hydroxyproline deposition compared with lacZ mice (400.4 ± 51.1 µg, 
208.9 ± 28.4 µg in ad-lacZ and ad-cav1 group respectively, P=0.0048, Figure 22I). 
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Figure 22 Cav-1 suppresses BLM induced pulmonary fibrosis.  (A) Adenovirus vectors 
containing the cav-1 gene and lacZ gene were administered intratracheally into C57BL/6 mice 
lung. After 7 days of infection, mice were sacrificed. Cav-1 expression was determined by (A) 
immunohistochemistry and (B) Western blot. The C57BL/6 mice infected with ad-cav-1 or ad-
lacZ or saline were treated with BLM for fourteen days. The lungs were harvested and subjected 
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to (C) H&E staining and (D) Masson trichrome staining of the right lung tissue. (Original 
magnification, x10) A representative example of four to five determinations was shown for each 
group in panel A and B. (E) Histology grade score analysis of the tissue slides. For groups 
without BLM, n=4; for groups with BLM, n=5. (F) Hydroxyproline content determination of the 
left lung. For groups without BLM, n=4; for groups with BLM, n=5. (G) ECM deposition and 
Smad-2 activation in the whole lung as determined by immunoblot analysis. (H) TGF-β1 content 
determination by ELISA of the homogenized protein of the whole lung (n=3 for each group). (I) 
Hydroxyproline content determination of the whole lung seven days after ad-cav-1 infection and 
fourteen days after BLM instillation (n=3 for each group). 
 
 
3.5 CAV-1 MODULATES TGF-β1 INDUCED ECM PRODUCTION VIA MAPK AND 
SMADS PATHWAY 
 
MAPK pathways are known to regulate TGF-β1 signaling and TGF-β1-induced ECM 
production. Cav-1 has been shown to modulate MAPK activation in mesangial cells. Here, we 
hypothesized that cav-1 might regulate TGF-β1 induced ECM production via the MAPK 
pathway. We first examined whether cav-1 affects MAPK activation in MRC-5. Consistent with 
previous reports, TGF-β1 markedly induced ERK and JNK phosphorylation within 10 min of 
treatment. Overexpressing cav-1 via an adenoviral vector significantly inhibited TGF-β1 induced 
ERK and JNK activation (Figure 23A). There was no apparent induction of p38 activation by 
TGF-β1 in MRC-5. The involvement of the ERK and JNK pathways was further explored using 
chemical inhibitors. Overexpressing cav-1 via adenovirus inhibited TGF-β1-induced ECM 
production in DMSO treated samples. In contrast, PD 98059 (inhibitor of MEK1) and UO 126 
(inhibitor of MEK1/2) administration eliminated the modulation of cav-1 on collagen type I 
production while having a negligible effect on fibronectin production (Figure 23B). SP 600125 
(JNK1/2 inhibitor), on the contrary, eliminated the modulation of cav-1 on fibronectin 
production while having no effect on collagen type I modulation (Figure 23B). Furthermore, 
pulmonary fibroblasts isolated from JNK1 null mice did not exhibit differences of TGF-β1 
stimulated fibronectin production between ad-lacZ and ad-cav-1 transfection, compared with the 
fibroblasts isolated from JNK1 wild type littermates (Figure 23C). These data suggested that cav-
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1 modulates TGF-β1 induced collagen type I production via the ERK1 pathway, while 
modulating TGF-β1 induced fibronectin production via the JNK1 pathway.  
We determined the regulation of Smads activation by cav-1 in human fibroblasts MRC-5 
with both gain of function and loss of function experiments. Similar as in mouse fibroblasts 
NIH3T3 (14), cav-1 suppressed smad-2 phophorylation and nuclear translocation. Moreover, 
overexpressing cav-1 effectively attenuated Smad-3 nuclear translocation and seems had no 
apparent effects on Smad-4 Smad-7 expression and Smad-4 nuclear translocation (Figure 24A). 
In consistent, down regulating cav-1 by siRNA transfection increased Smad-2 phosphorylation 
and Smad-2 / Smad-3 nuclear translocation (Figure 24B).  
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Figure 23 ERK and JNK pathway are involved in ECM regulation of cav-1.  (A) Western blot 
analysis of TGF-β1 stimulated MAPK activation for 0, 10 min, 30 min and 60 min in MRC-5 
cells infected with Ad-cav-1 or Ad-lacZ. (B) Western blot analysis of TGF-β1 stimulated ECM 
production in MRC-5 cells infected with Ad-cav-1 or Ad-lacZ. The cells were pre-treated with 
DMSO or PD 98059, UO 126 or SP 600125 for 1 hour, and then treated with TGF-β1 for 2 days. 
(C) Western blot analysis of TGF-β1 stimulated ECM production in pulmonary fibroblasts 
isolated from JNK1 (+/+) and (-/-) mice infected with Ad-cav1 or Ad-lacZ. Data are 
representative of three independent experiments. 
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Figure 24 Cav-1 modulates Smads activation. Western blot analysis of Smad-2 activation under 
different conditions in MRC-5. (A) Cells were infected with Ad-cav1 and Ad-lacZ; (B) 
transfected with siRNA targeting cav-1 and control for 24 hours. The cells were serum starved 
overnight and treated with TGF-β1 for 0, 10 min, 30 min and 60 min. Data are representative of 
three independent experiments. 
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We further investigated the involvement of JNK. JNK1 null mouse fibroblasts showed the 
similar suppressions of Smad-2 and Smad-3 phosporylation and nuclear translocation, 
mimicking the effects of over expressing cav-1 (Figure 25A), suggesting that cav-1 regulates 
Smad-2/3 activation via the JNK1 pathway. To clarify this hypothesis, cav-1 was over expressed 
in JNK1 wild type and null fibroblasts by adenovirus infection. As expected, cav-1 markedly 
suppressed smad-2 phosphorylation and smad-2/3 nucleus translocation in wild type fibroblasts 
(Figure 25B). Meanwhile, in JNK 1 null fibroblasts, over expressing cav-1 did not reduce smad-
2 phosphorylation and nucleus translocation, while it still suppressed smad-3 nucleus 
translocation (Figure 25B). To further investigate the role of JNK in vivo, we performed 
immunochemical analysis with the BLM treated lung fibrosis tissue. As shown in Figure 25C, 
phosphorylated JNK levels were dramatically high in saline and lacZ mice, while ad-cav-1 
infection markedly attenuated phospho-JNK. Moreover, JNK was highly activated in IPF tissues 
compared with the controls (Figure 25D), indicating its pivotal role in IPF development. These 
data strongly supported that JNK was involved in the regulation of ECM by cav-1. 
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Figure 25 Role of JNK in pulmonary fibrosis. (A) Immunoblot analysis of Smad-2 
phosphorylation in cytosolic extracts and Smad-2/3 levels in nuclear extracts. (B) Immunoblot 
analysis of smad-2 phosphorylation in cytosolic extracts and smad-2/3 existences in nuclear 
extracts in JNK1 wild type and null fibroblasts infected with ad-cav-1 or ad-lacZ. Data were 
representative of three independent experiments for panel A and B. (C) Immunohistochemical 
analysis of JNK phosphorylation in lung tissue slices treated with BLM and infected with ad-
lacZ or cav-1 or instilled with saline. Brown indicated phospho-JNK positive. A representative 
example out of five was shown. (Original magnification, x40.) (D) Immunohistochemical 
analysis of JNK phosphorylation in frozen lung tissue slices from IPF patient and control 
subjects. Green indicates phospho-JNK; blue indicates nucleus. A representative example out of 
seven samples for patients or control was shown. (Original magnification, x20.) 
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3.6 SUMARRY 
In this charpter, the role of cav-1 in the pathogenesis of IPF was extensively investigated. 
Cav-1 was first found to be reduced in the IPF tissue and lung fibroblasts. TGF-β1, the pro-
fibrotic cytokine, was demonstrated to decrease cav-1 expression in a dose and time dependent 
manner. The role of cav-1 on extracellualr matrix production was investigated using several 
independent methods. Overexpressing cav-1 with adenovirus infection and stable transfection 
significantly decreased TGF-β1 induced alpha smooth muscle, collagen type I and fibronectin 
production. Downregulating cav-1 expression using siRNA targeting cav-1 markedly increased 
TGF-β1 induced alpha smooth muscle, collagen type I and fibronectin production. To better 
understand the potential therapeutic effects of cav-1 in vivo, andenovirus cav-1 was 
administrated intratrachelly into mouse lung in a bleomycin-induced pulomary fibrosis model. 
Cav-1 gene was overexpressed by this virus infection. The extent of pulomary fibrosis was 
markedly suppressed by cav-1 overexpression, as revealed by histological exam, hydroxyproline 
content determination and western blot of matrix production. TGF-β1 cytokine production was 
also shown to be reduced.  
The mechanism was further investigated. ERK1/2 and JNK were induced rapidly by TGF-
β1 in MRC-5 cells while p38 seems to have no apparent induction. Up-regulation of cav-1 by 
adenoviral infection markedly attenuated ERK1/2 and JNK phosporylation. PD 98059 (inhibitor 
of MEK1) and UO 126 (inhibitor of MEK1/2) selectively block the inhibitory effects of cav-1 on 
collagen type I production but not fibronectin production. Interestingly, inhibition of the JNK 
pathway by the chemical inhibitor SP 600125 or genetic knock out selectively blocks the 
inhibitory effects of cav-1 on fibronectin production but not collagen type I production.Using 
adenovirus and siRNA transfection, cav-1 was demonstrated to suppress TGF-β1 induced Smad-
2 phosphorylation. Cav-1 was also found to suppress smad-3 nuclear translocation, but had no 
apparent effects on smad-4 and smad-7 expression. Further investigation using JNK1 null 
fibroblasts demonstrated same reduced Smad-2 phosphorylation and decreased Smad-2/3 nuclear 
translocations compared with the wild type fibroblasts. In JNK1 null cells, cav-1 lost the ability 
to suppress Smad-2 activation, while it was still capable of inhibiting Smad-3 activation. 
Moreover, phospho-JNK staining was markedly reduced in ad-cav-1 infected BLM-injured mice 
lung samples compared with lacZ or saline samples. Taken together with the fact that JNK was 
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highly activated in IPF lung tissues, our data indicates that cav-1 regulates TGF-β1 induced 
fibronectin production via JNK pathway, possibly via the modulation of Smad-2 phosphorylation 
and nuclear translocation. 
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4.0  DISSCUSION 
4.1  CAV-1 AND INFLAMMATION 
Cav-1, first identified about one decade ago, was reported to have many functions, 
including the formation of caveolae, membrane trafficking, regulation of signal transduction 
pathways, apoptosis,  as well as calcium and lipid homeostasis in fibroblasts, adipocytes, and 
endothelial cells (1). Recently, cav-1 was reported to be expressed in PMs and involved in the 
pathogenesis of atherosclerosis and inflammation (76). Although Kasper and colleagues found 
cav-1 staining in rat AMs by immunohistochemistry, they hypothesized that it was the result of 
phagocytosis of other cell-type debris (106). Thus, studies of cav-1 in AMs are absent, and little 
is known about the expression and function of cav-1 in AMs. In this study, we used two 
independent methods to detect cav-1 expression in murine AMs. Using Western blot analysis, we 
demonstrate that mouse AM expression of cav-1 is similar to that of the PM. Consistent with the 
notion that cav-1 is primarily a membrane bound protein (34), immunofluorescence staining 
demonstrated that cav-1 mainly colocalized with Mac-3 on the plasma membrane of primary 
mouse AMs. 
The macrophage is one of the major host immune defensive cells. It plays pivotal roles in 
phagocytosis, cytokine production, and antigen presentation (178). Many investigators are 
interested in the function of cav-1 in macrophages (179). Besides lipid metabolism, it is 
becoming more accepted that cav-1 modulates inflammation. Cav-1 suppresses inflammation via 
its interaction with and inhibition of eNOS activity (97). Leonard and colleagues reported that 
filipin and nystatin, drugs that specifically disrupt the caveolae microdomain by cholesterol 
chelation, impaired the entry of Chlamydia trachomatis serovar K. into J774A.1 cells (92). 
Satizo and colleagues showed that downregulation of cav-1 combined with upregulation of 
eNOS decreased leukocyte adhesion in pial venules of ovariectomized female rats (97). Bucci 
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and colleagues used the scaffolding domain of cav-1 to inhibit edema formation and vascular 
leakage to the same extent as glucocorticoid in rats (91). In our LPS-induced inflammation 
model, cav-1 has a direct effect on cytokine production in AMs and PMs. We chose siRNA 
technology to manipulate cav-1 levels in primary macrophages, resulting in a marked 
suppression of cav-1 expression. Because primary macrophages do not divide, the concentration 
of siRNA in each cell may remain high for a longer time than in fast-growing cells. Production of 
the proinflammatory cytokines TNF-α and IL-6 was greatly increased by the treatment of siRNA 
targeting cav-1, whereas production of the antiinflammatory cytokine IL-10 was markedly 
attenuated. Consistently, RAW264.7 cells stably transfected with cav-1 demonstrated a markedly 
attenuated proinflammatory cytokine (TNF-α and IL-6) production and increased 
antiinflammatory cytokine (IL-10) production. 
The MAPK and PI3K pathways are activated by many cellular stresses, including LPS, 
and are intimately linked with the regulation of cytokine production (97). ERK2 and PI3K were 
reported to localize in caveolae (1). These findings suggest that the MAPK and PI3K signaling 
cascades were attractive target candidates for cav-1. We have shown in this study, in a mouse 
macrophage cell line RAW264.7, that cav-1 selectively augmented p38 phosphorylation but 
inhibited JNK, ERK1/2, and Akt phosphorylation. The p38 inhibitor (SB203580) blocked the 
effects of cav-1 on LPS-induced cytokines production. In contrast, inhibition of the ERK1/2 and 
PI3K/Akt kinase cascades did not affect the modulation of cytokine production by cav-1. The 
pivotal role of p38 activation was further confirmed by studies on macrophages isolated from 
MKK3-gene–deleted mice. There are three MKKs that can phosphorylate the p38 MAPKs: 
MKK3, MKK4, and MKK6 (180, 181). Given that MKK3 is the major activator of p38, we 
administered LPS to MKK3 null macrophages and found that attenuation of the p38 by MKK3 
knockout led to a complete loss of the response. These results indicate that cav-1 affects LPS-
induced cytokine production through the activation of MKK3/p38. Using a chemical inhibitor, 
we also showed that inhibition of the JNK pathway reverses the modulation of proinflammatory 
cytokine IL-6 production by cav-1, while not affecting TNF-α and IL-10 production. Our data, 
along with the previous implication of the JNK pathway in the inhibition of macrophage 
cytokines production by carbon monoxide and heat shock (182), suggest that the JNK pathway is 
involved in the regulation of inflammatory cytokine IL-6 production. Although the conclusion 
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drawn from chemical inhibitor experiments alone is not convincing, it is likely that cav-1 has 
effects via multiple signaling pathways. 
It has been previously demonstrated that the effects of LPS on macrophages require 
recruitment of LPS receptor complex (TLR4 and MD-2) to lipid rafts containing CD14 (183). 
Walton and colleagues reported that LPS was capable of inducing membrane translocation of 
TLR4 and MD-2 to caveolar fraction in human aortic endothelial cells with cell fractionation and 
immunofluorescence analyses (89). Cav-1 has been reported to regulate membrane receptor 
signaling through direct binding or through the interaction of the downstream signaling 
molecules (184). TLR4 contains a putative cav-1 binding motif (739FIQSRWCIF747) (6). Our data 
here demonstrated that cav-1 interacts with TLR4 via the cav-1 binding motif and disrupts 
downstream adaptor molecules recruitment. The interaction of cav-1 and TLR4 is regulated by 
CO, which is generated endogenously in caveolae as the byproduct of HO activity.  After LPS 
stimulation, HO-1 translocates to caveolae via the p38 MAPK pathway. 
NK-κB and AP-1 are well-known transcription factors that regulate LPS-induced 
cytokine production (168). We explored the effects of cav-1 on NK-κB and AP-1 activation after 
LPS treatment. The results demonstrated that cav-1 markedly suppressed the activation of these 
two transcription factors as measured by EMSA. Given previous reports that p38 regulates NK-
κB and AP-1 activation in macrophages (185, 186), we hypothesized that p38 is involved in the 
suppression of NK-κB and AP-1 activation by cav-1. SB203580, the inhibitor of p38, 
consistently abolished the suppression of the transcription factors activation by cav-1. The exact 
mechanisms by which cav-1 and p38 modulate NK-κB and AP-1 will be the subject of ongoing 
studies. 
In summary, we have demonstrated cav-1 expression in mouse AMs. Cav-1 has a 
protective role for inflammation by suppression of proinflammatory cytokine (TNF-α and IL-6) 
production and augmentation of antiinflammatory cytokine (IL-10) production in the LPS model. 
We have also presented evidence that cav-1 interacts with TLR4 and the interaction is regulated 
by CO and HO-1, which trafficking to caveolae upon LPS stimulation. The effect of cav-1 
involves the p38 MAPK signal pathway. We speculate that increased LPS-mediated activation of 
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p38 and decreased activation of JNK, NK-κB, and AP-1 by cav-1 lead to protection against 
inflammation. Cav-1 is an important mediator of antiinflammatory effects.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26 Diagram of cav-1 and inflammation. LPS binds to and activates its receptor TLR4. 
The activated TLR4 recruits downstream molecules MyD88 and TRIF, which activated the 
downstream IKK kinase activity. IKK phosphorylates IκB, which promotes IκB degradation. 
Then p65 will be released and phosphorylated, followed by nuclear translocation. It also 
activates p38 MAPK pathway and transcription factor AP-1. Cav-1 confers its antiinflammatory 
effects via several pathways. (1) Cav-1 directly binds to TLR4 and disrupts TLR4 association 
with MyD88 and TRIF. (2) Cav-1 inhibits IKK activity as well as NF-kB p65 phosphorylation 
and nuclear translocation. (3) Cav-1 inhibits AP-1 activity. (4) Cav-1 activates p38, which 
promotes HO-1 caveolar translocation. Carbon monoxide is generated in caveolae due to HO 
activity there. Carbon monoxide increases cav-1 interaction with TLR4, which further attenuates 
the TLR4 signal.  
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4.2 CAV-1 AND FIBROSIS 
Although the etiology and pathogenic mechanisms of IPF remain unknown, a complex and 
poorly understood interaction of genetic and environmental factors appears to be involved (99). 
In this study we observed that the expression of cav-1 is significantly reduced in lung tissue and 
fibroblasts derived from IPF patients.  Our observations are consistent with previous reports that 
cav-1 expression is aberrantly regulated in experimental animal models of lung fibrosis (104-
106). Our data showing decreased cav-1 expression in lung tissue and fibroblasts might be an 
important indicator of impaired cellular functions of fibroblasts in the pathogenesis of IPF.  
Since IPF shows a distinct histopathology of usual interstitial pneumonia, a commonly held 
migration and proliferation, decreased apoptosis and enhanced release of fibrogenic growth 
factors. TGF-β1 is one of those major pivotal fibrogenic factors (176). It promotes myofibroblast 
transf tion, which is responsible for secreting large amounts of ECM, and presents only in 
fibrotic lung tissue but not in normal lung tissue (176). It suppresses ECM degradation through 
the re
While TGF-β  can promote the fibrotic progress, it decreased cav-1 expression in a dose 
and tim
view is that persistent interstitial inflammation leads to and modulates the development of 
fibrosis (187). This hypothesis is applied in clinic settings in that antiinflammatory therapies 
combined with immunosuppressive therapy are major strategies used in treating IPF, although 
the outcome is still poor (188). A new hypothesis has been advanced by Selman et al. that IPF is 
an epithelial-fibroblastic disease (189). Alveolar epithelial cell injury and activation will release 
many fibrogenic mediators, which lead to the transformation of fibroblast to myofibroblast and 
the formation of fibroblasts-myofibroblast foci, characterized by fibroblast-myofibroblast 
orma
gulation of metalloproteases and their inhibitors (190). TGF-β1 caused minor inflammation 
but marked progressive fibrosis in the lung. It has many diverse functions including 
chemoattractant and mitogenic activities, and the regulation of lung inflammation and functions 
of epithelial cells which might have further impact on the fibrotic process through autocrine or 
paracrine mechanisms (102). Transferring of the TGF-β1 gene into rat lungs via an adenoviral 
vector can induce a severe and progressive lung fibrosis (191). Blocking TGF-β1 can effectively 
reduce fibrosis in different animal models (102).  
1
e dependent manner in both human primary pulmonary fibroblasts and MRC cells. The 
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modulation in mRNA was in accordance with protein levels and suggested that cav-1 was 
regulated both transcriptionally and translationally. TGF-β1 was demonstrated to be produced at 
the sites of active fibrosis and its level in the lung was reported to be proportionate to the degree 
of fibrosis generated (102). The increased levels of TGF-β1 might contribute to the attenuated 
cav-1 expression in IPF patients. Consistently, myofibroblasts were reported to be lacking of 
caveolae as revealed by electron microscopy (192). 
Inhibition of TGF-β1 signaling was capable of slowing the progression of IPF when 
administered to patients (193). Here we showed that cav-1 can modulate TGF-β1 induced ECM 
production in vitro. Gain of function experiments demonstrated that exogenous cav-1 either by 
adenoviral infection or stable transfection in MRC fibroblasts markedly decreased TGF-β1 
induced α-smooth muscle actin gene expression, and ECM production including collagen type I 
and fibronectin. Consistently, loss of function experiments using siRNA showed that down-
regulating cav-1 expression in MRC fibroblasts increase α-smooth muscle actin gene expression, 
and ECM production in response to TGF-β1 stimulation. Cav-1 has recently been reported to 
regulate collagen type I expression through the ERK pathway in normal pulmonary fibroblasts 
(104). However, the current studies using several independent and complementary approaches 
are the first to extensively demonstrate that cav-1 can directly affect α-smooth muscle actin gene 
expression, and ECM production in a TGF-
ing (Figure 22D) and reduced fibronectin 
production (Figure 22G) as de
hydroxyproline content is not as impressive as histology examination scores. This may due to the 
low sensitivity of the assay or uneven distribution of virus and BLM in the left  right lung 
β1 stimulated fibrosis model, which is more similar to 
the pathogenesis of pulmonary fibrosis in vivo.  
The therapeutic effects of cav-1 on pulmonary fibrosis were further confirmed in vivo using 
a BLM-induced pulmonary fibrosis model. Overexpression of cav-1 by adenoviral gene transfer 
significantly decreased lung fibrosis scores (P < 0.01, Figure 22E) and lung hydroxyproline 
content (P < 0.05, Figure 22F) compared with lacZ virus, accomplished by attenuated collagen 
deposition as revealed by Masson trichrome stain
monstrated by Western blot. As we noticed, the reduction of 
 and
when the reagent is administered intratracheally through the mouth because of the asymmetric 
lung anatomy structure of mice. The improvement in BLM-induced lung fibrosis resulting from 
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treatment with the cav-1 adenovirus further supports the beneficial effects of cav-1 during 
pulmonary fibrosis.  
The anti-fibrotic effects of cav-1 are obvious and significant, which made the investigation 
of the molecular mechanism more interesting and important. Here, we examined the role of the 
MAPK signaling cascades in mediating the effect of TGF-β1 in collagen and fibronectin 
synthesis. The family of MAPKs consists of three known subfamilies including the ERK1/2, 
JNK1/2 and p38.  All these kinases are reported to be involved in the regulation of TGF-β1 
induc
. Interestingly, inhibition of the JNK pathway by the chemical inhibitor SP 
6001
ed ECM production and pulmonary fibrosis (194, 195). However, the effects and the 
pathways varied greatly depending on the cell types and conditions. In the present studies, 
ERK1/2 and JNK were induced rapidly by TGF-β1 even after 10 min treatment in MRC-5 cells 
while p38 seems to have no apparent induction. Up-regulation of cav-1 by adenoviral infection 
markedly attenuated ERK1/2 and JNK phosporylation. Cav-1 has been demonstrated to regulate 
ERK1/2 activation in a variety of cells including pulmonary fibroblasts, mesangial cells, bovine 
parathyroid cells, cancer cells and endothelial cells etc. It has also been shown that ERK 
localizes in caveolae and interacts with cav-1 directly (184). With respect to ECM regulation, we 
find that PD 98059 (inhibitor of MEK1) and UO 126 (inhibitor of MEK1/2) selectively block the 
inhibitory effects of cav-1 on collagen type I production but not fibronectin production. 
Previously, ERK1/2 has been shown to regulate collagen expression in pulmonary and dermal 
fibroblasts (157, 196)
25 or genetic knock out selectively blocks the inhibitory effects of cav-1 on fibronectin 
production but not collagen type I production. In a human fibrosarcoma cell line, similar findings 
were reported that JNK activation was essential for TGF-β1 stimulate fibronectin production, as 
stable transfection of dominant negative mutant of JNK1 markedly suppressed TGF-β1 
stimulated fibronectin mRNA and protein expression (197).  
Given the previous report that cav-1 interacted with TGF-βRI and transfection of a HA-tag 
cav-1 inhibited smad-2 phosphorylation in NIH3T3 cells (104), we postulated that cav-1 might 
modulates Smads activity. The effect of cav-1 on Smad-3, Smad-4 and Smad-7 has not, to our 
knowledge, previously been examined. Using adenovirus and siRNA transfection, cav-1 was 
demonstrated to suppress TGF-β1 induced Smad-2 phosphorylation, similar with the studies 
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before (104). Cav-1 was also found to suppress smad-3 nuclear translocation, but had no 
apparent effects on smad-4 and smad-7 expression. 
Further investigation using JNK1 null fibroblasts demonstrated same reduced Smad-2 
phosphorylation and decreased Smad-2/3 nuclear translocations compared with the wild type 
fibroblasts. In JNK1 null cells, cav-1 lost the ability to suppress Smad-2 activation, while it was 
still capable of inhibiting Smad-3 activation. Moreover, phospho-JNK staining was markedly 
reduced in ad-cav-1 infected BLM-injured mice lung samples compared with lacZ or saline 
samples. Taken together with the fact that JNK was highly activated in IPF lung tissues, our data 
indicates that cav-1 regulates TGF-β1 induced fibronectin production via JNK pathway, possibly 
via the modulation of Smad-2 phosphorylation and nuclear translocation. 
In summary, we have demonstrated that cav-1 is capable of inhibiting the production of 
matri
mad-2 activation by cav-1 regulated JNK 
pathw
x molecules by fibroblasts, and exogenous transfer of cav-1 can inhibit the pulmonary 
fibrotic response in a BLM rodent model.  We have also shown that cav-1 inhibited TGF-β1 
induced collagen type I production via the ERK pathway, and fibronectin production via JNK 
pathway. We found that cav-1 mRNA and protein expression were low in lung tissues and 
fibroblasts of IPF patients. We postulate that one of the mechanisms for the phenomenon is 
through TGF-β1, which was shown to be an effective regulator of cav-1 expression in pulmonary 
fibroblasts. We delineated that the inhibition of S
ay. Our study strongly supports a pivotal role for cav-1 in ECM regulation and suggests a 
novel therapeutic target for patients with pulmonary fibrosis. 
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Figure 27 Diagram of cav-1 and fibrosis. TGF-β1 activates downstream kinases activity. Smad 
2/3 are phosphorylated and translocates into nucleus. JNK and ERK pathways are activated.  
These will result in a-SMA, fibronectin and collagen I productions. Cav-1 performs its anti-
fibrotic effects via several pathways. (1) Cav-1 inhibits JNK and ERK activation. (2) Cav-1 
inhibits Smad 2 phosphorylation and Smad 2/3 nuclear translocation. (3) Cav-1 inhibits 
fibronectin production via JNK1 pathway. (4) Cav-1 inhibits collagen I production via ERK 
pathway.  
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4.3 THE RELATIONSHIP OF INFLAMMATION AND FIBROSIS 
Fibrosis is usually regarded as the terminal stage of inflammation. Inflammation relates to 
brosis in various diseases and organs.  
For instance, pulmonary fibrosis is a common response to various injuries of the lung 
cluding pneumonia (99). The pathogenesis of pulmonary fibrosis includes endothelial and 
pithelial cell injury, production of inflammatory cells and their mediators, and fibroblast 
ctivation (99, 189). The terminal stages of fibrosis are characterized by proliferation and 
rogressive accumulation of connective tissue replacing normal functional parenchyma, despite 
the different initiating factors (99). Although antiinflammatory therapies combined with 
ents against pulmonary fibrosis (100).  
IPF is a chronic inflammatory disease. Inflammatory processes injure the lung 
parenchyma, modulate the proliferation of mesenchymal cells and result in the fibrotic change 
(101). Numerous cell types’ interactions and activations are following after the lung injury (101). 
Lung injuries including exposure to inorganic dusts
inflammatory cells, such as macrophages (101). The oxidants and/or proteases produced by 
macro
ement of the lung parenchyma (101, 189). Subsequent 
chang
fi
in
e
a
p
immunosuppressive therapy are ineffective in preventing progression of the disease, these 
strategies remain the major and conventional therapy in treating fibrosis (100).  Further 
understanding of the molecular mechanisms of inflammatory reaction, fibroblast proliferation, 
endothelial and epithelial cell apoptosis, collagen deposition should lead to the development of 
effective treatm
 or viral infection may trigger activation of 
phages and neutrophils lead to further injury to the alveolar epithelium and capillary 
endothelial cells and result in the derang
e of pulmonary interstitium is characterized by the accumulation of mesenchymal cells 
such as fibroblasts and deposition of connective tissue production in the alveolar walls (101). 
Inflammatory cells have been extensively suggested to play pivotal roles in the 
pathogenesis of pulmonary fibrosis (101, 188). Macrophages at first may release oxidants and/or 
proteases. It recruits and stimulates fibroblasts (198, 199). Later macrophages lead to the 
production of prostaglandins, which lead to suppression of macrophage, neutrophil, and 
lymphocyte responses (200, 201). This leads to attenuating tissue injury and the development of 
fibrosis (202). Macrophages are also considered to play a major role by secreting large amount of 
growth factors and cytokines (102). Neutrophils may initially damage parenchyma via releasing 
 80 
toxic metabolites and enzymes (203). However, they may later attenuate fibrosis, perhaps 
through collagenase secretion (204, 205). Lymphocytes may initially participate in a number of 
damagi
nd 
macrop
overall TNF-
ng ways by secreting chemotactic factors and participating in destructive autoimmune 
processes (206). However, certain subpopulations of T cells may markedly shift during the 
process of fibrosis, leading to attenuation of the development (207-210). Granulocytes, 
eosinophils and mast cells are also involved during the development of pulmonary fibrosis (211-
217).  More recently novel mechanisms have been proposed: bone marrow-derived stem cells 
may play a crucial role in the fibroproliferative response and epithelial regeneration (218-220). 
A variety of biological substances can modulate the development of pulmonary fibrosis, 
including cytokines, chemotactic factors, and adhesion molecules (102). These cytokines include 
TGF-β, TNF-α, PDGF, TGF-alpha, IL-1, IL-6, monocyte chemoattractant protein (MCP)-1 a
hage inflammatory protein (MIP)-1 α, etc (102). These cytokines secreted by activated 
inflammatory cells, such as macrophages and eosinophils, as well as noinflammatory cells, such 
as myofibroblasts and epithelial cells, exists at the sites of active fibrosis (102). Studies have 
revealed a variety of potential roles of the cyokines, including chemoattractant, mitogenic 
activities for fibroblasts, stimulation of extracellular matrix and alpha-smooth muscle actin 
production, alteration of the contractile phenotype of fibroblasts and regulation of diverse 
functions of lung inflammatory and epithelial cells (102). Besides TGF-β, a complex network of 
cytokines is responsible for the fibrotic process rather than any single cytokine. It is the balance 
of profibrogenic and antifibrogenic forces generated from interaction among the various 
cytokines in the network, which finally determines the outcome of lung injury (102). TNF-α  
promotes fibroblast proliferation and chemotaxia, which appears to be profibrogenic.  It also has 
antifibrotic property, such as inhibition of collagen production (221-224). Studies in vivo 
demonstrated that neutralization of TNF decreased inflammatory cell accumulation and 
pulmonary fibrosis in BLM-induced injury (224, 225). TNF-α transgenic mice, which 
overexpress TNF-α in the lungs, develop interstitial pneumonitis (152). This indicates that 
α is a pro-fibrotic cytokine. IL-6 is a major cytokines released by activated 
macrophages (226). It is secreted in BAL fluid in BLM-induced lung injury model (227). IL-6 
modulates neutrophil and B cell activation (228, 229). Neutralization of IL-6 and/or TNF in vivo 
markedly attenuates MIP-1α expression (230), which is an important anti-fibrotic cytokine, as 
neutralization of it dramatically suppresses pulmonary fibrosis in mice (231). 
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The present study demonstrated cav-1 serves to inhibit inflammatory cytokines 
production including TNF-α and IL-6 in alveolar macrophages. It also suppresses myofibroblasts 
transformation and production of ECM in pulmonary fibroblasts. Taken together with the reports 
that cav-1 has anti-proliferation effect in epithelial cells and fibroblasts, our study suggests that 
cav-1 will become a promising target molecule for therapy of lung injury.  
 
 
 
 
 
 
Figure 28 Diagram of cav-1 effects in lung injury.  
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APPENDIX A 
[MATERIALS AND METHODS] 
Cell Culture, Animals and Reagents. Primary peritoneal and alveolar macrophages were 
intained in 10% fetal bovine serum (FBS) Dulbecoo’s modified Eagle’s medium (DMEM).  
RAW264.7 cells were grown in 5% FBS DMEM (Gibco-BR). Cav-1 stably transfected 
RAW264.7 cells and vector control cells were generated and maintained as described previously 
(232). Cultures were maintained at 37º C in a humidified atmosphere of 5% CO2 and 95% air. 
ma
The cells were serum starved before 100 ng/ml LPS stimulation. C57BL/6 mice were purchased 
om Jackson Laboratory (Bar Harbor, ME) and acclimated 1 week before experiments. All 
lines from the American Association for 
Laboratory Animal Care and Research Protocols and were approved by the Animal Care and Use 
Committee of University of Pittsburgh School of Medicine. PD 98059 (10 µM), UO 126 (10 
µM), and SP 600125 (10 µM) (Calbiochem, Darmstadt, Germany) were dissolved in DMSO. All 
reagents were added to the culture medium 1 hour before other treatments. MKK3 (-/-) mice 
were generated as described before.  Wortmannin (100 nM), SB203580 (10 µM), SP600125 (10 
µM) and UO126 (10 µM) (Calbiochem, Darmstadt) were dissolved in DMSO. All reagents were 
added to the culture medium 1 hour before other treatments.  
Human Tissues, Samples and Cells. This study was approved by the Institutional Review 
Board for Human Subject Research at the University of Pittsburgh. Human lung tissues were 
obtained from the tissue bank of the Department of Pathology at the University of Pittsburgh. 
Diagnosis of IPF was supported by history, physical examination, pulmonary function studies, 
chest high-resolution computed tomography (HRCT), bronchoalveolar lavage findings, and 
corroborated by open lung biopsy. The morphologic diagnosis of IPF was based on typical 
fr
animals were housed in accordance with guide
 83 
microscopic findings consistent with usual interstitial pneumonia. The patients fulfilled the 
criteria of the American Thoracic Society and European Respiratory Society (233). Age, race, 
and sex matched control samples, included normal histology lung samples from patients with 
lung cancer or healthy subjects died from t, were obtained from the Pittsburgh 
Tissue Bank. Fibroblasts were derived from lung tissue obtained at autopsy from IPF and 
controls were maintained in 10 % fetal bovine serum (FBS) Dulbecco's modified Eagle's medium 
(DMEM) with 50 µg/ml gentamicin. Primary lung fibroblasts were isolated from JNK1 (-/-) 
mice and wild type littermates tal lung fibroblasts (MRC-5) 
(purchased from the American Type Culture Collection, Rockville, MD) were maintained in 10 
% FBS DMEM. MRC-5 cells were cotransfected (1:10) with pcDNA3.0 containing the 
ashed off twice with PBS after 3 
 traffic acciden
 as described before (234). Human fe
neomycin selection marker, the expression vector pCAGGS containing cav-1 cDNA in the sense 
orientation, or with the pCAGGS control vector. Transfected cells were grown in DMEM, 10% 
FBS containing G418 (200 µg/ml). Cultures were maintained at 37 ºC in a humidified 
atmosphere of 5 % CO2 and 95 % air. Cell culture reagents were purchased from Gibco-BR. The 
cells were serum starved before TGF-β1 (R&D Systems, Minneapolis, MN) stimulation. TGF-β1 
was reconstituted in sterile 4 mM HCl containing 0.1% bovine serum albumin (BSA).  
Isolation of peritoneal macrophages and alveolar macrophages. The experimental protocols 
were performed in accordance with the guidelines of institutional animal care & use committee 
(IACUC) of University of Pittsburgh. Briefly, after the mice were anesthetized with isoflurane, 
peritoneal macrophages were isolated by peritoneal lavage with 2 ml PBS each time for 3 times. 
For alveolar macrophages isolation, mice were tracheotomized after transection of the abdomen. 
A blunt 21-gauge needle was secured into the trachea. Bronchoalveolar lavage (BAL) was 
performed 5 times with 0.3 ml phosphate buffered saline (PBS). Cell pellets were collected after 
centrifuging at 1000 g for 10 min at 4º C. The supernatant was discarded and the cells were 
resuspended in 10% FBS DMEM. Unattached cells were w
hours culture, and the remaining macrophages were incubated overnight in DMEM 
supplemented with 10% FBS. On the following day, cells were washed twice again before 
treated as indicated. 
Synthesis and Transfection of Small Interfering RNA (siRNA).  siRNA sequences targeting 
mouse cav-1 gene were designed using software (Dharmacon, Inc). Among the five siRNAs 
synthesized, two sequences with better effects (AAAGAUGUGAUUGCAGAACCA; 
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AAUCAGCCGCGUCUACUCCAU) were used. The sequence 
(AACGCGCACACCAAGGAGAUU) with no apparent effects was used as a negative control. 
SiRNA sequence targeting human cav-1 gene (AA CCA GAA GGG ACA CAC AGT T) was 
synthesized (Dharmacon, Inc. Lafayette, CO). The sequence (AA CGC GCA CAC CAA GGA 
GAT T) targeting the mice cav-1 gene with no apparent effects in human cells was used as a 
negative control. For transfection, cells were plated on 6-well plates or 24-well plates. 
Transfections were performed with TransIT-TKO reagent (Mirus Corp) as directed by the 
manufacturer. For 6-well plates, each well received 10 nM siRNA in a volume of 1ml in 
triplicate. For 24-well plates, each well received 2 nM siRNA in a volume of 200 µl in triplicate. 
For macrophages study, cells were plated on 24-well plates. LPS was added after 24 hours of 
transfection. For fibroblasts study, cells were plated on 6-well plates. Other treatment was added 
after 24 hour of transfection.  
Cytokine Analysis. The level of cytokines (TNF-α, IL-6, and IL-10) released by LPS stimulated 
macrophages into the culture supernatant were measured by enzyme-linked immunosorbent 
assay (ELISA) kits (R&D Systems), following the manufacturer's instructions. 
Western blot analysis. Cells were rinsed with ice-cold PBS and homogenized in lyses buffer 
av-1 polyclonal antibody was purchased form Santa Cruz (Santa Cruz 
(1% NP-40, 20 mM Tris pH 8.0, 137.5 mM NaCl, 1 mM Na3VO4, and 1 mM PMSF) with 
complete protease inhibitor mixture (Roche Diagnostics). The supernatant was collected after 
centrifugation for 20 min at 14,000 g at 4° C. The protein concentrations were determined by 
Coomassie (Bradford) protein assay kit (Pierce Biotechnology Inc.) with bovine serum albumin 
as a standard. A total of 50 to 100 µg proteins in each sample were subjected to electrophoresis 
through a 4-12% SDS-polyacrylamide gel (Novex). The proteins were electro transferred onto 
polyvinylidene difluoride membrane (Immobilon-P). Membranes were blocked in TTBS buffer 
(Tris-buffered saline with 0.1% Tween 20) containing 5% low fat milk for one hour and 
incubated overnight at 4 °C with the corresponding primary antibody. After washing with TTBS, 
membranes were incubated for 2 hours at room temperature with the corresponding secondary 
antibody. Membranes were washed again and developed with ECL reagent (Amersham 
Biosciences). Anti-c
Biotechnology Inc). Anti-mouse ß-actin monoclonal antibody was purchased from Sigma (Sigma 
Chemical Co). Total and phosphorylated forms of MAPK were from Cell Signaling Technology.  
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Immunofluorescence Microscopy. BAL cells were seeded on cover slips at a density of 
5× 104/well (24-well). Cells were rinsed 3 times with PBS and then fixed in 2% 
paraformaldehyde. The cover slips were then sequentially incubated at room temperature in PBS 
containing 4% goat serum for 60 min, and immunostained with polyclonal rabbit cav-1 and Mac-
3 antibodies in 0.5% bovine serum albumin/PBS for 60 min. Bound primary antibodies were 
visualized with Cy-3 and Alexa 488-conjugated secondary antibodies (Jackson ImmunoResearch 
Laboratories). Cells were viewed with an Olympus Fluoview BX 61 confocal microscope and 
images were collected using a DC-330S cooled CCD camera (DAGE-MTI Inc.).  
Electrophoretic Mobility Shift Assay (EMSA). Nuclear protein extracts were made as 
described previously (136). Double-stranded oligonucleotides containing the transcription factor-
binding site for AP-1 (5'-CGCTTGATGAGTCAGCCGGAA-3') and NF-κB (5'-
AGTTGAGGGGACTTTCCCAGGC-3') (Promega, Madison) were labeled with 32P-ATP using 
yacrylamide gels. 
RT-PCR was performed in triplicate in 40 µl reaction volumes consisting of 1x PCR buffer A, 
T4 polynucleotide kinase (Promega, Madison) as described. Four micrograms of nuclear proteins 
were incubated with the probe in binding buffer (Promega, Madison) for 20 min at 37º C. The 
reaction mixture then was subjected to electrophoresis through 5% native pol
The gels were dried and exposed.  
Purification of RNA and Quantitative RT-PCR. Total RNA was isolated from lung fibroblasts 
or cell lines with TRIzol reagent using the manufacturer's protocol (Invitrogen, Carlsbad, CA) 
and cleared with Rneasy Mini kit  (Qiagen, Hilden, Germany). The reverse transcription (RT) 
was performed with reagents from Invitrogen. Isolated RNA was first incubated with random 
hexamer at 65°C for 5 min for annealing. The optimal RT reaction was then carried out in 20 µl 
volumes consisting of 1x RT buffer, 1 µl of SuperScript II reverse transcriptase, 1 µl of 
RNaseOUT, 5 mM MgCl2, 0.5 mM each dNTP, 0.01 mM DTT, 5 µmol/L random hexamers, and 
500 ng total RNA. Reactions were incubated at 25°C for 10 minutes, 48°C for 30 minutes, and 
95°C for 5 minutes. "No RT " controls were carried out in all samples using the same RT 
reaction mix but substituting DEPC-H2O for SuperScript II reverse transcriptase. PCR primers, 
fluorogenic probe (Taqman) and all other reagents were purchased from Applied Biosystems 
(Applied Biosystems, Foster City, CA) (human cav-1: Hs00184697_m1; human beta-
glucuronidase: Hs99999908_m1) and used following the manufacturer's protocol. Quantitative 
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3.5 mM MgCl2, 0.3 mM dNTP, 0.025 U/µl AmpliTaq Gold, and 4 µl of the RT reaction. Two-
step PCR cycling was carried out as follows: 95°C 12 minutes x 1 cycle, 95°C 15 seconds, 60°C 
1 minute x 40 cycles. At the end of the PCR, baseline and threshold values were set in the ABI 
7700 Prism software and the relative cav-1 expression were calculated as described before (235). 
Cav-1 Adenovirus construction and Infection. Cav-1 cDNA were inserted into a pAdlox 
plasmid. Cav-1 and LacZ adenovirus productions were performed by the Vector Core Facility in 
University of Pittsburgh. For cell infection, 2 x 105 MRC cells were cultured in 6-
7
well plates and 
ssues were frozen in liquid nitrogen and subjected to 
immunohistochemistry.  The 6-µm tissue sections were washed three times in 0.5% BSA 
exposed to 2 x 10  plaque-forming units of each virus in 1 ml of serum-free medium for 4 hours. 
The cells were then washed and incubated in serum-containing media for 36 hours. The cells 
were then subjected to other treatment as indicated. For animal infection, 1 x 1011 plaque-
forming units of each virus in 50 µl of PBS were administrated intratracheally per mice. After 7 
days of infection, mice were sacrificed. Cav-1 expression was determined by immunoblot and 
immunohistochemistry. 
Immunohistochemistry. Briefly, lung tissues were fixed in 2 % paraformaldehyde for 2 h and in 
30% sucrose overnight. The ti
(Sigma-Aldrich), and blocked for 1 h in 2% BSA. After three washing of the samples in 0.5% 
BSA, tissue sections were incubated with the cav-1 antibody at a dilution of 1 to 5000 (Santa 
Cruz Biotechnology) for 1 hour. The samples were then washed 5 times in BSA and incubated 
with Cy3-conjugated goat anti-rabbit Fab fragment (Jackson ImmunoResearch Laboratories, 
West Grove, PA) for 1 hour. After 5 washing in BSA, the sections were incubated with the Alexa 
fluor 647 phalloidin (Invitrogen) for 1 hour. Samples were washed 5 times in BSA and PBS. 
Hoechst dye (Sigma-Aldrich) was added for 30 seconds, and samples were washed in PBS and 
then mounted. Tissue sections were viewed with an Olympus BX51 fluorescent microscope 
(Olympus America, Melville, NY). 
Bleomycin Administration. After 2 days adenovirus infection, the mice were lightly sedated 
with isofluorane. Bleomycin (BLM) (Bristol-Myers Squibb, Princeton, NJ) at a dose of 0.075 
U/mouse in 50 µl of sterile saline was administered intratracheally by canulation of the trachea 
via the mouth with a 20-gauge feeding needle.  
 87 
Hyproxyproline Assay. After fourteen days of bleomycin administration, the left lungs were 
harvested and dried at 110°C until a constant weight was obtained. The dried lung was 
hydrolyzed under vacuum in a glass vial containing 1 ml of 6N HCl at 110°C overnight. The 
samples were lyophilized and assayed for hydroxyproline content using a chloramine-T method 
as previously described (236). 
o
 production follows a normal distribution as tested by Anderson-Darling 
aplotypes were estimated using the resulting genotypes by 
Histopathology. The right lungs were fixed in 10% formaldehyde for 24 hours and then 
processed for paraffin embedding. Sections of lung were stained with routine hematoxylin and 
eosin or with a Masson trichrome stain to assess the degree of fibrosis. The extent of lung 
fibrosis was graded by a pathologist in a blinded manner on a scale of 0 for normal lung to 8 as 
previously described (236).  The major criteria examined included interstitial thickening of 
alveolar or bronchiolar walls, collagen deposition, and inflammatory cell infiltration. Sc res were 
then averaged per treatment group and compared to control using ANOVA analysis.  
Statistic Analysis. The differences in cytokine expression were compared by unpaired Student’s 
t test, since the cytokines
goodness-of-fit test. The variances are equal across groups as verified by the Bartlett test. All 
analyses were performed with SPSS 12.0.1 for Windows, and were considered significant at p < 
0.05. The differences in mRNA level of cav-1 expression determined by quantitative RT-PCR 
were compared by Student’s t-test. The differences in protein level of cav-1 expression 
determined by immunoblot analysis were compared by Wilcoxon two-sample test. For animal 
experiments, differences in measured variables between experimental and control group were 
analyzed using ANOVA. Groups containing multiple comparisons were assessed by analysis of 
variance, and Bonferroni’s correction was used in determining P values. All analyses were 
performed with SPSS 12.0.1 for Windows, and were considered significant at p ≤ 0.05. For 
promoter polymorphism studies, each case-control comparison we computed standard χ2 tests of 
independence between genotype distribution, allele frequency, haplotypes and phenotype. P-
value ≤ 0.05 consider significant. H
disease status using the Genetic software of SAS. Allele and genotype specific odd ratios were 
estimated. Hardy-Weinberg equilibrium test and all statistical analysis were performed using the 
Genetic software of SAS. 
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 APPENDIX B 
[ABBREVIATES] 
ry fibrosis (IPF) 
Interferon-γ (IFN-γ) 
Interleukine-1 (IL-1) 
Active protein-1 (AP-1) 
Alveolar macrophages (AM) 
Bleomycin (BLM) 
Bronchoalveolar lavage (BAL) 
cAMP-activated protein kinase (PKA) 
Carbon monoxide (CO) 
Caveolin-1 (cav-1) 
Chest high-resolution computed tomography (HRCT) 
c-Jun N-terminal kinase (JNK) 
Dulbecco's modified Eagle's medium (DMEM) 
Electrophoretic Mobility Shift Assay (EMSA) 
Endoplasmic reticulum (ER) 
Endothelial nitric oxide synthase (eNOS) 
Epidermal growth factor receptor (EGF-R) 
Extracellular matrix (ECM) 
Extracellular signal regulated kinase (ERK) 
Fetal bovine serum (FBS) 
Harvey rat sarcoma viral oncogene (H-Ras) 
Heme oxygenase-1 (HO-1) 
High density lipid (HDL) 
Hydrogen peroxide (H2O2)   
Idiopathic pulmona
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Interleukin-5 (IL-5) 
Interleukin-6 (IL-6) 
Interleukin-10 (IL-10) 
Lipopolysaccharide (LPS) 
Macrophage inflammatory prot
Mitogen-activated protein kinase (MAPK) 
Monocyte chemoattractant protein (MCP)  
Nitric oxide (NO) 
B) 
e-3 (PI3K) 
tor (PDGF-R) 
NA) 
NaAsO2) 
 
ein (MIP) 
Nuclear factor-κB (NF-κ
Peritoneal macrophages (PM) 
Phosphoinositide kinas
Platelet-derived growth factor recep
Reactive oxygen species (ROS) 
Small Interfering RNA (siR
Sodium m-arsenite (
TGF-β receptor I (TGF-βRI) 
Toll like receptor 4 (TLR4) 
Transforming growth factor β  (TGF-β ) 1 1
Tumor necrosis factor-alpha (TNF-α)  
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